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Ang:otensln-converting enzyme (ACE), a zinc rneta lloproteaoo. is a i;ey 
regulator of the mammalian renin-angiotensin system (RAS) Primanly, ACF 
is a dipeptidyl pepi idase which cieaves angootensin I to [)roduee angiote!lsin 
!I a potent vasoconstrictor, By the same enzymatic me(.hanisrn, ACE 21 1'30 
inoctivates the vasodi lator bradykinin. The main overall effect of these actions 
is an increase in blood pressure Several ACF ,nhibilors have been developed 
as drugs for the treatment of myocardial mfarction, hyperten"ion, kidney 
failure and heart failure 
There are two major Isoforms of ACE somatic and tc~t lS ACE (sACE and 
lACE respecti ve ll'J Somatic ACE consists of a C- and N-domain, wh ile testis 
.ACF is essentially identical to Ihe C-domaill Both forms llf ACF are heavily 
glycosylated, a fact that has complic.;ated the structural determination of the 
enzyme Discovery of the wlo-domain structure of sACF led to the real isation 
that the two domains had different ill vivo functions, and that the selective 
regulation of these domains by drugs might lead to Improved eff icacy and 
reduced unwanted effects. The side effects of treatment with ACE inhibitors 
have :ncluded ongloedcmo and cough. and have been attnbuted to the 
accumulation of bradykinin. 
There is ample evidence to suggest that the selective inhibition of only the C-
domain may lead to the desired reduction in hloo(1 pressure and leave the N-
domain unhindered to continue functioning physiologically (for example, 











The three-dimensional structural information on tACE and the N-domain. as 
well as other ACE homologues. has allowed both insights into and speculation 
about the differences (putative and obsel'led) between the N- and C-domains 
A better understanding of the determinants Df domain selectilfity is the maJDr 
goal of this project The C-domain-selectlve inhibitor, RXf-'A380, IS one of the 
most C-domain-selecli'.e cDmpDunds currently availab!e {K, (C-domain = 3 
nM, cf K; (N-domain) = 10000 nM) 
The co-crystal lisation of tACE-g13 a tUlly functional glycosylatim mutant of 
tACE with RXPA380 has enabled the determination by X-ray crystallography 
of the structure Df the tACE·g13~RXP,ll.380 complex, to a reSOlution of 2.7 A. 
This provides new InfDrmation on the binding of the carboxybe zyl P2 grOl'P, 
The set of interactions between the S2' reSidues and the P2" tr',ptophan side 
chain appears to be as predicted the major determinant of the selectiVity Df 
RXPA380, as cOlllpansons with the N-domaln suggest In particular, the 
interaclions of the indole ring with two valine residues af1d of the indole 
noLrogen with a water mDlecule that also has a hydrogen bond to a glutamic 
acid appear to be the main stabilising interactions. The ill silica modelling of 
the tACE~RX PA380 complex gives an inhibitor conformatlDn that. for the most 
part. corresponds well to the crystal structure 
The determination 01 the structure of tACE-g13 compiexed with this Inhibitor 
confirms the utility of the glycosylation mutant as a structural tool in drug-
binding studies It also provides Important insights into the determinants cf 
selectivity, and thus may aid the design of next-generation inhibitors that are 
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1.1. General biochemistry & substrates 
Angiotensin-converting enzyme (ACE) is a vital catalytic component of the 
mammalian renin -angiotensin system (RAS) a coordinated hormonal 
cascade that controls blood pressurE. renal function, and ftuid and eiectrolyte 
homeostasis (Skeggs, Jr. et al. 1956: Erdos & Skidgel, 1987: Ehlers & 
Riordan, 1989) Briefly, ACE cleaves the otigopeptides angiotensin i (Ang I) 
and bradykinin (8K) to produce angiotensin II (Ang II , vasoconstrictor) and 
bradykinin ,_, (8K,_,. inactivated vasodilator) (Fig. 1-2) The inhibitiOn of ACE 
activity has been known for a 1011g time to result in the alle''';ation of 
hypErtEnsion (Erdos & Skidgel, 1987) ACE occurs In most tissues, but is 
primarily found in the vascular tisslJes of IlJrlgs and ~.idneys (Ehlc"s & Riordan, 
1991, Ehlers et a! , 1991b). The rolE of ACE in the RAS, and the interplay 
between the local RAS and circulating RAS ha',Je bEen pre\liously re\liewed 
(Campbell. 1987: Dzau, 1988; Danseretal 1999). 
ThE gel1e codil1g for ACE has two promoter sites (Soubrier Et al 1993). ACE 
is a membrane-anchored zinc metalloprotease with two homologous domams, 
each contam!J1g an active Site (Soubner et ai, 1988: We! et ai, 1991) It is a 
dipeptidyl pEptidase, clea\ling the pEnultimate peptidE bond from \larious 
oIlgopeptide substrates (or their analogues) and releasmg a shGrtened 
oligopEptide and a C-terminal dipeptide 
The aim of this review is to describe the basic biochemical and catalytic 
properties of ACE. evaluate thE Insights gamed from structural studies of ACE 
and rElated metalloproteases, and propose a line of investigation that will 
further thE undErstanding and appHcation of domain-selective ACE inhibitors 
1.1.1. ACEisoforms 
The non-vertebrate isoforms of ACE, such as the Drosopilila mcianogastcr 
AnCE generally lack mEmbrane anchors and are therefore soluble (Coates et 
aI., :!OOO) [here arE two major Isofo~ms of mammalian AC E, somatic ACE 










surface of vascular endothel ial cells. in lung capillary cells . and in the brush 
I:torder (epithelium) of ~.idney tubules while testis ACE is found in male 
germinal cells (Erdos & Skidgel, 19137: Baudln, 2002) (Fig. 1-1). Both isoforms 
are expressed from a single ACE gene. Somatic ACE is the fult protein with 
1306 amino aCids (but excluding exon 131. and includes a 29·amino acid N· 
terminal signal pepllde (Soubrier et al.. 1988), On the other hand lACE is 
Identical to the C!ermma! aomain of sACE but lor its own 31·ammo aCId N· 
terminal signal sequence plus the unique O--glycosylation·rich N·termlnal 
sequence erxoded byexon 13 (Baudin, 2002) Somatic ACE is shed hy 
proleolysis from the cell membrane into the bloodstream Testis ACE is 
cleaved more efficiently, suggesting some sort of regulatory role for the N· 
domain (Sadhukhan et al 1998 Woodman et al., 2000) The clea'vage site IS 
located at the R""·S"'"I:to!1d (Ehlers et aI., 1996; VVoadman et al 2000). 
although the identity of the shedding enzyme(s) is unknown 
Testis ACE (tACE) 
I C·domain 
. ., 
fT. t~. reglOn 'l 
- Cylus<>lic ldil i 
Figure 1·1. Schematic mpmsent.tion of lACE ~nd sACE isoforms N-linked 
g!yco~yIM",n sites am r~pre~ent"" by Y .... haped symbols 
Two further forms of human P,CE have been isolated Ndomain ACE from 
ileal fluid (Deddish et ai, 1994), and N-domain ACE from the urine of mild 
hypertensive palients (Casarini et ai 2001) The latter findi ng, of a 90 kDa 
form of N-domain ACE; has also been confirmed in spontaneously 
hypertensive rats artd has been considered for use as a possible genetic 










of ACIO are proouced by proteolytic cleavage after release of the full lerlgth 
ACE from the membrarle (Oeddish et aL 1994: BuerlO et al 2004). 
Arlgiotensin-COrlvertirlg enzyme II (ACE2l IS a recerltly discovered 
carboxypeptidase that removes only the C-terminal reSidue from Arlg I givirlg 
angioterlsirl, _" It is transcribed trom a different gene ar;:j has a sirlgle catalytic 
site (Crackower et al , 2002; Oudlt et al 200.3) 
1.1.2. Glycosyfation 
ACE is heavily glycosylated, with up to 30% OT the mo!ecular weight of tACF 
being due to N-lirlked ar;:j O-lirlked glycans (Ehlers et al 1992) 0-
giycosylatlOll occurs irl the N-termirlal regiorl that is urlique to tACE. and could 
ptay a role in the bindmg of sperm to oviduct epithelium during the process of 
fert,l'satlorl. However, thiS region is rlot critical to Its structure or erlzymatic 
fUrlctlorl (Ehlers et al 1992 Kasturi et ai, 1994; Baudin et al . 1997) 
N-linked glycosylatiOrl occurs by means of a highly regulated series of 
enzymatic reactions. The N·linkage is betweerl the side-chairl amide of arl 
asparagine residue and the deslgrlated C1 of N-acfltyl gIUcosam;ne, ' .... h:ch is 
in turn typICally linked to a series of other glycan residues. This glycosylatiorl 
can only occur at asparagine (N) residues that are fourld in the "glycosylation 
sequon" N-X-S/T, where X is any amino acid except proline (Ronin et al _ 
1981) 
In mammalian cells , highly diverse chains of N-linked glycans may occur, With 
the result that the surfaces of otherwise identical molecules can be highly 
heterogeneous Somatic ACE contains 17 potential N-linked glycosylatiorl 
Sites 7 of which are m the C-domam. The C-termmal site is not glycosylated 
while sites 4-6 are partialiy (i .e. m some instances) glycosylated arld sites 1-3 
are fully (i e invariably) glycosylated (Yu etal , 1997) (Fig 1-1) 
A minimal level of glycosylatiorl protects the erlzyme from irltracellular 
degradation while targeting it for extracellular secretlOrl, arld the 











1997) The solubility in extracellular medium may also b8 dependent on the 
presence of sufficient glycans on the surface of the enzyme (Baudin et al 
1997). Stud!es using synthetic membranes have also revealed a li~ely role of 
carbohydrates in mediating the dimerisation of ACE (Kost et 011 1998; Kost et 
011 . 2000) 
Most critically to structural studies, the glycosylallon of .<I.CE has pr8sented a 
major obstacle in the ~ucidation of its three-dimensional structure (Gordon et 
011.. 2003; Sturrock e! aI., 20(4). Because glycosylation as a process is not as 
strictly controlled as code-directed polypeptide synthesis tMre is a high 
d89re8 of oligosaccharide heterogeneity amongst molecules at identical 
glycosylation sites (Yu et al 1997). This means that crystallisation, which 
requires regular packing of id8ntical structures, is very d,fficult to achi8ve to 
the standard reqUired for structural analysis using X-ray crystallography, Two 
successful approaches to reducing the heterogeneity and aiding crystallisation 
have been a-glucosidase I inhibition to produce uniform, truncated N-iinked 
glycan chams (Yu 8t 011, 199?), and the mutagenesis of some asparagi!1e 
residues to glutamine thus preventing N-glycosylatlon (Gordon et al ZOO3) 
The IACE-lisinopril structure (idenlical to the C-domaln) solved by means of 
the former approach was the first published structure of any ACE isoform. and 
revealed that in fact all the putative N-Imked glycan cilalns were at the surface 
of the enzyme (Natesh et 011 Z003), More recently, the structure of the ACE 
N-domain. express8d in the presence of a-glucosidase I inhibitor N-
butyldeoxynojirimycin (NBDNJ). has been rep<Jr1ed, revealing similar surface 
glycosylation (Corradi 81 ai., 20(6), Wat8rmeyer et ai. (ZOO6) have solved the 
firs! lACE mutant structure, using a form of lACE (named IACE-g13) in which 
all but the first and third glycosyiation sites have been removed by 
asparaglne-to-glutamine mut:'lgenesis, In addition, the structure of Drosophila 
analogue AnCE (using bacu!ovirus expres~on in Insect cells) has been 
determined With only two of three pOSSible glycosylation Mes Intact (Kim 81 
011, 20(3), although it is known that AnCE is active e\jen when unglycosylated 
(Williams et ai, 1996). A third approach, the expression of lACE in insect cells 
USing Baculovirus infectlOll (Williams e! al , 1994) has also yi8!ded protein that 










1.1.3. Chloride activation 
It has long been !-:nown that ACE is activated by monovalent anIOns. In 
particular chlorrde which is the anion typically found associated with ACE 
under physkllogical conditions (Bunning & Riordan. 1983). The dependel1Ce 
of ACE on chloride was found to vary with substrate structure, so that for 
example. angiotensin I hydrolySIS is more dependent on chloride than is 
bradykinin hydrolysis (Shapiro & Riordan. 1984). It has been suggested that 
the presence 01 positlvel,' charged residue (KJR) at the C-termmus of a 
peptide results in greater mdependence from chloride. Thus. BK,., 
accumulates In the absence 01 chloride whereas in presence of chloride Doth 
BK,.r and BK,., are produced. The dependence of the two domains on 
chloride also dilters. ne C-domaln is Slgnitican~y more dependB!1! on 
chloride activation than the N-domaln (Jaspard et al. 1993) K, inhibition 
values for three commercia l inh,bitors of ACE In ditterlng ch loride 
cOl1Centrations (Wei et al . 1992), suggested a chloride-indlICed 
conformational change that occurs In the C-domalll (and therefore tl\CE) but 
not in the N-domain (Natesh et al 2004) pH is also a determining lactor in 
the chlonde activation (WeI et al . 1991 Bersanetti et al. 2004). The 3-
dimensional structure of tACE revealed the locatIOns of two chloride ions 
buried In the interior of ACE (Natesh e! al 2003). Their mechanism of 
activation of ACE remains elusive. and appears to be IIldlrect as CI ' and CI' 
are 20.7 A and 104 A from the catal,'tlc zinc. respectively 
1.1.4. ACE substrates 
In the 1950s. ACE was identified as a factor in horse blood that cleaved 
angiotenSin I to produce the vasoactive angiotensin II (Skeggs. Jr et al 
1956) and IMependently as a bradykinin-inactivating enzyme, km:nase 
(Erdos & Yang. 1967) {reviewed by Erdos & Skidgel, (1987)) It has since 
been found to cleave several other groups of substrates (Sturrock et al , 












DRVYIHPF IlL angiotensin I 
DRVYIHP FH anglotensin , _9 
RPPGFSP FR bradykinin 
RPPGF SF bradykinin, 7 
RPKPQQFFG substance P 
RPKPQQFF GLM" substance P 
,EHW SGLRPGp GNRH 
Figure 1_2. Natural ACE substrates and th .. ir ck>avag .. ~ it&s. ,;ndic~tes protvclion by 
amidation. 
1.1.4.1. Angiot nsin 
Angiotensin I (a decapepl,de, sequence DRVYIHPFHL) is the best-known 
substrate of ACE Angiotensin II type I (AT,) r8C8ptor~ (mainly in heart and 
vi35Cular smooth mu~c l e cells) are the primary mediators of the vasopr8ssor 
effects of angiotensin II which result in th., upregi.latiO(l of systemic blood 
pressure (Erikssorl et al. 2002; Turner & Hooper, 2002; 8alldin, 2002) 
Angioten~in II also binds AT, roeceptors, wtlich may count.,r the .,/feets of AT, 
receptors, and are also considered respOIlsible for cell proliferation, 
differentiatiOll and angiogenesis (Turner & Hooper. 2(02) After the discovery 
of the t..vo-domain nature of the enzyme (SOUDrler et al , 1988 , Soubrier et al , 











peptide bond in angiotcnsm I. releasing angiotensin II and the C-tenninal HL 
dipeotidc. There is Ml absolute l ine requlrell)(lnt by both domains as 
indicated by EDTA inhibition, and affinity (indicated by K" values) for 
angiotensin I IS similar in both domains (Wei et al.. 1991), However there are 
significarlt differences in their catalytIc ratc, chloride activatiorl, arld pH 
deOE:mderlcy (Wei et ai " 1991, Wei ct al 199~ ; .Iaspard et ai, 1993) 
Cleavage of ang;otensin I is more chlorioo-dependcmt than that of bradykinin 
(Shapiro & Riordan, 1984; Jaspard et ai , 1993) Additionally, for angiotensin I 
hydr~ysis the N-domaln is conSloorably less dependent on chloride 
activation, wh(Hcas the C-domam has an absolute requiremerlt for chloride, 
and fUrlctiorls optimally at a chloride concentration that IS inhibitory to the N-
domain (Wei et ai , 1991 ' Jaspard ct ai, 1993). Takcn together, thesc 
observations mdicate that the C-domain is resporlsible for most of the!fl I'H(I) 
hydrolysis of angioterlsirl I Experi ments u~ng highly selective Inhibitors 
against the C- and N-dQmams have confirmed thallhls IS also the case in vi'io 
(Georgiadis et al 2003) Interestingly, it was also fO<.lr1d that in I'lvo there 
seems to be a measure of cooperativity between the two domains since 
either an N-domain-speciflc or a C-domain-specific Inhibitor reduC!ld Arlg I 
hydrolYSiS 10 ncgligible level" akin to the effect of double inhibition 
(Georgiadis et ai, 2003) In addition stroog evidence for negative 
cooperativlty betwoon the domains has also been iwnd in bovlnc somatic 
ACE although this was with th€ artificial substrate FA-Phe-Gly-Giy (Binevski 
el al , 2003). 
1.1.4.2. Bradykinin 
Bradykinin (BK) is a nonapeplide (RPPGFSPFR) whose sequential dipeptidyl 
hydrolySIS by ACE leads to the production of two inactivated peptides BK, ., 
(RPPGFSP) and BK,_, (RPPGF) (Ehlers & Riordan, 19891 After 
carboxypeptidase activity has removed the C-terminal arginine. ACE is able to 
cleave the C-terminal tripeptide (SPF} from the octapepttde, thus performing 
an erldopeptldase !urlcliorl (Erdos & Skidgel 1987; Baudin, 2002). Jaspard 
and colleagues (1993) found that both N- and C-domains catalytical ly cleave 











Bunning and Go-wor •. em (1983). As with angiotensin hydrolysis. the C-domam 
was found to 00 more chlOride-dependent, although the extent of BK-
hydr~ysis dependence on chloride was less than that of Arlg I. 
1.1.4.3. N-domain preferred substrates 
As SOOrl as the presence of "'10 active $ites m ACE was confirmed (Wei et 211 
1991) studie$ were carned out to investigate the differerlces in their substrate 
selectiVIty and cata lytic efficiency, There were already hints that differences 
may exist based on studie$ done on well-kr.own substrates as wei! as 
ar!ific.ial $ubstrates of ACE Gonadotropm-releasing hormone (GnRH 
sometimes called Luteinisillg hormone-releasing hormorle (LHRH) in older 
literature). acts on the pitUItary gland to ir-.crease the reiease of gonadotropin 
and foll !cle stimulating hormone, GnRH was foulld to Dilld sACE somewhat 
mefficielltly (K,,-167 ~M) (Skidgel & Erdos. j985) but the N-domain 
demonstrated greater catalytic activity INith thiS substrate (Jaspard et 211 
1993), ACE releases tripeptides from both the N-termina! and C-terminal 
ends. It call atso sequentially cleave dlpeptide$ from the C-termmus after 
release of the C-terminal tnpephdyt to produce tne N-termma! tripeptide 
(Skidgel & Erdos. 1985) 
,III-acety1-seryl-aspartyHysyl-proline (Ac-SDKP) is a natural tetrapeptide 
involved in the regulation of haematopoietic stem cell proiiferatioll It inhibits 
the entry of these pluripotent cells into S-phase (DNA replicatioll) and thus 
restricts proliferation It may al${) be an Important endogenous negabve 
regulator of fibroblast prolifera tion in the heart. thus redUCing fibroSIS and 
playing a cardioprotective role (Rhaleb et 011,20(1) Ac-SOKP is cleaved by 
ACE at the D-K bond to release Ac-SD alld KP, More $pecifically, It was found 
that the hydrolysis of Ac-SDKP occurs primarily at the N-domairl, which is 50 
times more catalyticaliy effiCient than the C-dornaln for the substrate 
(Rousseau et 211 , 1995). Captopril i$ an effective inhibitor of this hydrolysis. 
both in vilra (Rousseau et al 1995) and III VIVO (Azizi et 211, 1990) 
Arlg' _1 is a product of Ang I metabOlism via several dlffererlt pephdases, sllch 











been found to playa Significant role in the regulation of angiOtensin 
metabolism, primarily as it competitively inhibits the somatic ACE C-domain 
In addition, Ang,_, is cleaved by the ACE N-domam to give Ang,_, (Oeddlsh et 
al. 1998) 
1.1.4.4. C-domain preferred substrates 
Substance P is a neuropeptide with the sequence RPKPQQFFGLM" (Erdos & 
Skidge: 1987) ACE cleaves ihe C-terminal dipeptide and tripeptide from this 
undecapeptide although the physiological significance of this is unclear. The 
C-oomain demonstrates four-fold higher catalysis to the tripeptide against 
both its production of the dipeptide and the N·domain"s production of the 
tripeptide The C-terminal methionirl€ residue is said to be protected by 
am!datlon (Erdos & Skidgel, 1987). II has been proposed that the presence of 
an amide group on the C-termlnus of Substance p , GnRH and other 
substrates provides leeway for the peptide substrate to Slip', allowmg 
cleavage of the C-terminal tripeptide rather than or in addition to the dipeptide 
(Kim et aI., 2003) 
ACE has also been found to cJea'le other neuropeptides in Vitro, such as 
neurotensin. as well as several enkephalins (Erdos & Sk!c1gel, 1987) 
1.1.4.5. Artificial substrates 
A number of artificial substrates have been developed fo r enzymological 
studies of ACE. These tend to be shorter than natural peptide substrates. and 
typically contain peptldeS or peptidomimelic residues linked to a moiety that is 
detectabie by fluorimetric, radiometric . photometric, or other means for 
enzyme assays (8audin, 2002). They are often commercially available and 
easier to acquire them some peptide substrates. These include Z·Phe-His· 
Leu, hlppur)rI-histidyl-leucine (H H L), arld furylacrfloyl-phenyiaianyl-glycyl-
glycine (FA-Phe-Gly-Gly) The lalter two demonstrate the pattern of 











chlonde col'lcentratlon for HHL hydrolysIs by the N- and C-domalns of 10 al'ld 
800 mM respectively (Wei et al 1991). 
In a fascinating study Araujo and colleagues (2000) used fluorescence 
resonance energy transfer and several peptide sequenGes to determine some 
of the amino acid preferenGes of the C- or N-domail'l, panicl~arly at the Pl' 
poslt!on With a similar protocol, Bersanetti et at (2004) have developed a 
series of shon fluorogenic pepMe substrates, one of which (peptide sequence 
LFK) has showl'l (-70-fold) select,vlty for the C-domain 
1.1.5. Enzyme mechanism 
In both the N- and C-oomains of ACE, there is a conserved catalyllc 
seqllet1Ce that is characteristic of the gluzincin family of zinc metalloproteases 
(Hooper, 1994), The consensus sequence conSists of the HEXXH motif, the 
two histidines of WhfCh coordil'late the Zinc atom and a glutamic acid, (24 
residues downstream), which is the third zinc-coordinating residue 
The mechamsm of action of ACE was thOllght to mimic that of the prototypical 
zinc meta!loprotease thermorfsin. whose mechanism of action was ~ucidaled 
in several studies and summarised by Matthews (Fig 1-3) (Matthews 19B8). 
Briefly, the reactoon in ACE proceeds as a fairly typical general-base catalySIS 
A water molecule associated to the zinc attacks the carbonyl carbon of the 
SCissile bond of the substrate The glutamic acid (E""") of the metalloprotease 
signature HEXXH motif acts as the acceptor of a protOI'l from the water, The 
negatively charged oxygen resulting from the binding of OH is stabilised by 
073 d the zinc. as well as Y - ar1d a water;n this interme iate (in thermolysln these 
correspol'ld to a histidine and tyrosine, respectiv~y) As the reaction 
proceeds, the E- releases its proton to the amine nitrogen, thus destabilising 
the scisSile bond This bond's nitrogen atom is stabilised by electrostatIC 
interactoons with the backbone carbonyls of A'''' and S'"" The consequef1t 
charge repulSion between the new amino terminai and zinc, as well as the 
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Figure 1-3. Catalytic mech~njsm oftACE, ad~plcd from Matthews (1988) 
1.2. ACE inhibitors 
The first ACE inhiblt()rs were discovered as bradykinin-poientiatirog pep tides 
from the venom of the South American snake Bothrops jararaca as wel l as 
other venomous 511akes (Cushman et ai, 1977; Cushman & Ol1detti. 1999) 
Based on these, a good understanding 01 the carboxypepbdase A active site, 
and some modest computer modelling capabilities , Cushman and co-workers 
devel()ped capl()pril \\/him became the first dlnically-appro'led inhibitor ()f 
ACE (Cushman el al 1977: Ondetti et al 1977). Many d;fferent ACE 
Inhibi tors have been designed since then - as of 2002 there were seventeen 
different il1llibitors of ACE in clinical use (Zaman et al . 2002) The inhibitors 
can be categorised into major types determined by the number of amino acid 
~ubst'tuent groups Type I inhibitors have four amino acid (substituent) 
groups, designated P2, PI (on the N"terrr',inal side of the zinc-binding group), 
P1' and P2" (C-terminal groups) (Schechter & Berger, 1967). Type II inhibitors 
have PI PI' and P2' groups only, while Type III consist only of the C-terminal 
PI' and P2' groups and the ZinC b:nd;ng group (fig 1-4). An alternative 
clllsSl fi cation promotes the chemical character of the zlflc-biridlng motif IlS ihe 
major criterion for classification By this means, CClmpounds can be clustered 
into SIX classes IRedelinghuys et al 2005)-
• Su!phydryls - captopri ! is the prototype member of this group The 
inhibitor's coordination With the catalytic zinc atom is via a C-terminal -
SH group. These inhibitors are alSO known as Type III inhibitors, as 











• Ketones - (his group of compoul1ds includes both Type I and Type II 
molecules. Coordination to the zinc atom is by means of the ketone 
functional group 
• Carooxylates - as the name suggests the carboxy tate moiety is 
responsible for binding to zinc. Many of the clinical inhibitors belong to 
this group, and as they tend to be peptides or peptide analogues Ihey 
are often delivered to the body as eslers to implove bioavailabi1ity This 
group includes ena!apr!! and iismopri l, two well-establiShed anti-ACE 
drugs. 
• Hydroxamates - Turbanti and coworkers (TUlbanti el al ., 1993) 
pioneered the development of Type III inhibitors WIth a new ZIIlC-
binding moiet,. the hydroxamlc acid funciional group. Too non-amino 
acid nalure of Ihe compounds and too slereocOOmistry potential playa 
role in making the hydroxamates an alternative group of interest 
• Silanediols - these compounds take advantage of the ability of silicon 
to form a stable dlalkylSllanediol (Kim & Sieburth 2004) Since silicon 
does net form double bonds except under duress, this form can act as 
a stable (llilhydrolysable) mimic of the tetrahedral intermediate that 
forms during substrate catalysis. In addition silanediols are neutral at 
physiological pH, unlike hydrated carbonyl isosteres (Kim & Sieburth 
2004; Kim et aI., 2005) 
• Phosphinates - this functional group of compoul1ds has been long 
Known as potent inhibitors of zinc metalloproteases (Ylotakis et al , 
1994) Recently domain-selective Type I inhibitors have been 
developed that show n",nomolar inhibition constants selectively for one 
or other of the domains of ACE (DiVe et al.. 1999: Junot et al .. 2001 



























Figure 1·4, Chcrni~.1 strlJ{;tures arid inhibitor types 01 a range 01 ACE ",hibitors, The 
inhit>itor ~,oieties are positioned so as to indicate the ACE adi"" sit" sub·site that 











1.3. Three-dimensional structure of Angiotensin-
converting enzymes and related metalloproteases 
1.3.1. Introduction - metalloproteases 
The prototypical metalloproteases for ACE in terms of tertiary structure have 
been thermolysin and carboxypeptidase A (Colman et al 1972, Lipscomb. 
1933) The structures of these two metalloproteases have both been known 
for over 20 years, and indeed the active site of carboxypeptidase A was used 
as a mOdel for ACE in the early days of inhibHor design (Cushman et at, 
1977: Ondetti et ai, 1977) Structures of other metalloproteases have been 
~ucidated Both teukotrietle 411 hydrolase/aminopeptidase (Thunnissen et al , 
2002) and neutral endopeptidase or neprilysin (Defner et al 20(0) have 
catalytic Sites that are notably similar to that of tACE 
The structure of neurolYSIn a representative of the M3 family of 
metallopeptldases revealed an el!lptica l protein conta ining a narrow channel 
that limits access to the active site (Brown et al. 20(1), This discovery heloed 
to explain the s,ze range restriction of neurolysm substrates Like ACE, 
neurolysln IS able to hydrolyse a range of substrates but its major 
physiological substrate IS the important neuropepticle neurotens'n 
(pEL YQNKPRRPYIL), from which the C-termmal tripeptide is cleaved Apart 
from the zH'\C-blnding motif. there is no significant sequence simi larity between 
neurolysin and ACE however. the three·dimensional structures of the two 
metalloproteases are quite similar (Acharya et (ll " 20(3) 
The structure of a carboxypeptidase from the extreme thermophile 
Pyror:occils furiOSI1S, was found to bear a stflk:ng resemblance to the 
neurolySin structure, afld therefore to tACE (Arndt et al ,2002) This enzyme 
runctlons optimally at a temperature between 90°C and 100°C, and more 











adivity when various other metals, such as cclJalt are bourld (Cheng et al" 
1999) 
It appears that the overall architecture of the zinc metalloproteases allows for 
a variety of corlformations arid diverse sequences for differing enVIronments 
arid particular functions, with a premium conservation of the catalytic motIf 
1.3.2. ACE structures - C-domainltACE 
Several crystal structures of arlgiotensin-converting enzyme and its 
homolDgues have been solved recerltly The following sectlorls descnbe these 
crystal structures AI! the angiotensin-converting eflzyme homologues 
(truncated to exclude trans-membrane and irltracellular domams m the case of 
lACE and ACE2) have overall e!!lptlcal structures. The active site IS contained 
within a cavity or groove at or near the centre of the molecule 
1.3.2.1. Testis ACE (10Ba) and tACE-lisinopril (1086) 
Testis ACE was expressed and crystallised in the presence of an a-
glucosKiase I inhibitor (Gordorl et al 2003) The three·dimerlsional structure 
was datermlned by X-ray diffraction The molecule IS a predominantly helical 
structure, with only a few short ~-strands interrupting the dominant helices (20 
a- and 7 3"'-helices) that are separated by short loops (Natesh et al , 2003) 
(Fig 1-5, Fig 1-6) The a-helices 1 and 2 comprise the "top I,d" at the N-
termmal end of the molecule. preventing access of large substrates to the 
active site (Fig 1-6) A central groove extending about 30 A into the molecule 
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Figure 1 5. Sequence--structure alignment of human tACE. J<I-<lom.in ACE, ACE2 and 
Of050plljJa AnCE, generated with CLUSTALW (CMnna et ~ I .. ~003). The HEX)(H catalytic 
zinc"binding motif and zinc-coordinating glutamate are shown in ",d font; J<I~ink"d 
glycos yl~tion s equons ue in bold blu<> itolics; residues likely to interact with ligand 
(distanoe <; 5 A) a'" oold .nd unde,li""d. S<>condary structure is indicated by highlighting' 











The zinc-binding motif, HEXXH (in tA.CE XX = Me) with a downstream E residue 
(24 residues after the second histidine) firmly places ACE with thermolysin In the 
gluzincin family of zinc-conrdinating met<ll!oproteases (Riordan. 2()()3) although 
it sh<lfes neither sequence nor structural similarity nutside the ac1ive site with 
thermolysm 
The zinc ion <It the active site of the native structure of tACE was found to be 
coordinated with the two histidines of the HEXXH zinc-binding mnlif the 
downstream gllJtamat>! (E"'). ant! <In acetate ion, w~ch probably came from the 
crystallisation buffer (Natesh et al 2(03) (Fig 1-7) 
Large·scale mohon between the apoonzyme and the jn~bltor-txlund form was 
not evident from the two structures, although the presence of the <lGetate 
molecule as <l ligand in the native structure may have prevented such an 
observation, Modelling and analysis of the normal modes of tA.CE have revealed 
that there IS a likely opening and closing motiun abuut a hinge region similar to 
that found In ACE2 (To\o',ller et ai, 2()()4; Watermeyer et ai, 20(6) \Nithout this 
mution it is difficult 10 envisage how large substrates can gain access to the 
enclnsed active site 
Lisinopril is a substituted N-carbaxyalkyl dipeptide (Patchett et aI., 1980) with 
ACE K, values in the sUb-nanomoiar range (Wei et al. 1992 Jaspard et al 
1993). In the lisinopri l-bound structure of tA.CE, the inhibitor molecule is bound in 
an extended conformation with the zmc atom in this complex cnordinated by 
oxygen of the phenyl c<lrboxyli'lte group. which <lIsa forms a hydrogen bond w:th 
' n the hydroxyl of Y' The other nxygen of this carboxylate forms a hydrogen bond 
with the carboxylic acid side chain of E3il4 (probably protonated as crystallisation 
was carried out at pH 4.7) The m~bitor reSidues (or analogues thereof) <lre 
named USing the nomenclature first pr(lPosed by Schechter and Gurger 
(Schechter & Berger. 1967) The phenylpropyl group (p1\ is closest to the N-
terminal lid helices. and makes van der Waals' contacts with hydroPl lOblc 
reSidues The Iysyl grnlJP (prj IS parallel to the HEXXH-contaln1ng heli>: (0-13) 
The carbonyl group nf the Iysyl residue has dear hydrogen bands to two 











A""" (Fig. 1-7) The Iysyl side chain amine interacts with side-chain carboxylates 
of the Sl' subsite via wa ter molecules (Natesh et al 2004). The carlJ.oxyl group 
of the prolyl (P2') moiety faces away from the zinc-coordination site and is H-
bonded to tr.e r.ydroxyl group Of y"'O ami side chain amine of K"" (Fig. 1-7). The 
prolyl group fits into the rather large hydrophobic 52" subsite surrounded by 
hydrophobic residue side-chains y S23, F"7 al1d F"27 Residues E, m V370 and V'"" , 
wh ich are on the same u-13 he li~ as the HEXXH-mo!if also occur in the v icinity 
of the 52' subsite occupied by the P2' prolyl 
Figure 1-6. Th .... e·di<l1en~ ional strlictli'" of tACE-.o.~6NJ complexed with lisinopril (purplo 
sticksl (pdb code 1086, (Nate5h et al., 2003)1. Tho cartOOt1 representation i" coloured in 
rainl>OW MquenCe (N-terminl" dar!< blue, C·term;nu" in r~d l . Tho catalytic zinc and bound 
chloride ions are represonted as metallic blue and green 5pheres, rMp..ctively_ Some of 
the a_holices ~ .... I~ bclled, including the two lid helices at the top of the figure, ~nd o_holi. 











1.3.2.2. tACE-captopril (1uzf) & tACE-enalaprilat (1uze) 
The structure of Ihe same minima!ly glycosylated lACE complexed with captop'i ' 
has also been determined (Natesh et al 2(04). Captopril (D-3-mercapto-2-
methyl-propanoyl-L-proline) was one of Ihe first inhibitors of angiotensin· 
converting enzyme to be approved clir'1;ca!ly and commercially marketed as an 
ar1tihypertensive drug (Cushman et al 1977 Ondelti et al.. 1977 Cushman & 
Ol"\detti. 1980). II is one of the smaller ACE inhibitors available. occupying only 
the zinc·blnding site and tne S1' and 82' subsltes but It binds vel)' strongly \~1th a 







Fi9ur~ 1·7. Alignm ~nt of ACE inhibitors lisin"pril (orange), .. nalaprilal (purpl~) ~nd 
captopril (biu~) (structure" frCHtl pdb fil lOS 1086. 1uzc and 1uzf re$pcctiv~ly), The 
enalaprii"t is just visible as an almost-pcrt~cl superimpOSition on lisinopril. Active "ile 
r..sidues and catalytic ~ifIC (spll",r .. ) ar .. lak~n from tll.-. naliv .. lACE struclure (pdb code 
l<>8~ I, 
The binding of the captopril molecule at the active site occurs via the sulphydryl 
and the zinc ion Since this is not a carboxyl (as in the case of lisinopril) , there is 
no additional coordinatioo 10 y ' i.3 As with lisinopriL the carbonyl group of the PI' 











H"J The C-terminal carboxylate has much the same coordination as lisinopril. 
Because of its small size, the captopril molecule makes much less use of the 
contacts avai!able in the S1' and 52' subSites tnan Inhlbllors such as Ils!nopril, 
and trandolapri!at 
Erlillapri lal, a compound that is identical to li5inopri lon the N-terminal side (i.e at 
the P1 group), has the binding interactions that would be expected of the P1 
phenyl propyl. the phenyicarbo.ylate and the P1' r;ilrhony1 groups Enalaprilat is 
also identical to captoprll on the C-terminal side (from the alanine side chain In 
S1 'J, and so the same interactions are found 
1.3.3. ACE structures - N~domain 
The N-domain of ACE has been found to have different substrate and inhibi tor 
selectivities and binding characteristics (described In the relevant sectiOns) 
Experimental structures of the ACE N-doma!n - the native form and in complex 
with lisinoprll - have been recently ptlbilShed (Corradi et al 2006) Prior to this, a 
number of groups attempted to predict the N-domaln structure, based on the 
structu re of tACE (Tz:akos et aI., 2003; Fernandez: et al 2oo3) (see modelling 
section). 
The three·dimensional structure of the N-domain to 3 A re\lea!ed a \lery similar 
overall structure to the C-domain Consistent with the kno'Niedge that the N-
domain is less chloride-dependent (Wei et ai, 1992) only one ch loride ion 
position was found in the structure, and this site corresponds to that of chloride II 
In tACE, The largest N-terminai heiices form a lid structure with closely 
associated glycan residues, similar to that found In tACE No conformation 
difference was found oo!wflen !h,; apoenz:yme and the liganded form , probably 
fo r the same reason as with tACE - the presence of an acetate molecule in the 
native enz:yme active site The differences between the N- and C-domain acti\le 
sites W8re found to be attributable not only to differing res,dues at corresponding 
positions (Table 1), especially in the S1' and S2' sub-sites, but also due to sl ight 
sMts in helical positions and residue side-chain orientations For example, R'"" 











orientated the same way as the corresponding TO"'- of tACE. This provides jusi a 
hint that domain selectivity may involve the Interp lay of suvera; levels of related 
determinants, of which predicted conformat ional fit may be just one 
Table 1. Active site residues that differ between ACE N- and C-dom.ins (Corradi et ~I" 
2006) 
S2 tACE/C-domain E0J F'§I V~1 A 
N-domain R"" y""" TM 
g, tACEfC-domain V'" S"" E' '3 
N-domaln TM N'"' S " " 
S1' tACE/C-domain E161 N= 8 7&1 C-"7 N'R' C"" - V'" N-domaln D'" D'-"~ E,-62 RJ~a r'~'- D3~' N31{; T iM 
I,;u' "1-""""', """., vv _, . ____ 
'" . -''''' _ <.11 
the enzyme is relevant to Its intracellular protection and stabi lity (WIliams et al . 
1996) 
Biochemical studies have indicated that AnCE may resemble the C_domain 
rather than the N-domain of ACE For example, the AnCE hydrolysIs kinetics of 
Ac-SDKP (a predominantly N-domain substrate) resemble those of the C-
domain, and the chloride dependence with Hip-HL as substrate !s I:ke that of the 










since knocking out the AnCE gene has a negati'.e effect 0., fertility (Tatei et al 
1995) 
The structure of AnCE, a homologue of ACE found ,n Orosoplilia mefanogasler, 
was published soon after the lACE structure had been S()jved (Kim et al _ 2003j , 
The structure of AnCE is overall similar to tACE in that it is giobular, hydrophoboc 
and predominan~y a-helical AnCE shares just 42% sequence identity with tACE 
however this figlJre exceeds 70% in the areas around the active site of the 
enzyme (for both lACE and the ACE N-domain) (Fig, 1-5) The catalytic residues , 
structure (and presumably mechanism) are conserJed betv.een the two enzymes 







Figu.-.. l_B. Th~ 51' p<>ck~t of ACE. N· domain (green, pdb cod~ 2c6n) and lACE (blu~ , pdb 
code 10B6) ~Iigned, with residues differing betw""n dorn~in5 labelled with ~ppropri~te 











The structure of AnCE (Kim et aI., 2003) revealed a large internal channel 
running along the length of the entire molecule. As in tACE, the channel is 
composed of two chambers of unequal size, with the catalytic zinc occurring at 
the narrow segment between the two chambers. 
The zinc ion in the native state is penta-coordinated to two water molecules, the 
conserved histidines H383 and H387 (tACE numbering) and the downstream 
glutamate E411 of the HEXXH ... E gluzincin motif. By means of hydrogen bonding, 
D415 coordinates the zinc indirectly via H383 (Kim et a!., 2003). Captopril binds 
AnCE with a similar nanomolar Ki to ACE. As with tACE, the sulphydryl group 
binds to the zinc atom, completing the distorted tetrahedral geometry with the 
active site histidines and glutamate. The carbonyl of the alanyl (P1') residue 
coordinates with two other histidines, H353 and H513, as well as with y523. The 
carboxyl group of the P2' proline residue is held by hydrogen bonds and ionic 
interactions with Q281 , K511 and y520. All of these are conserved in both domains 
of sACE. It has been proposed that this "locking mechanism" restricts ACE to 
dipeptidase activity, except in the case of substrates that are amidated at the C-
terminus (Kim et a!., 2003). ACE can release the C-terminal tripeptide from such 
substrates, for example substance P and GnRH (Erdos & Skidgel, 1987; Ehlers 
& Riordan, 1989), suggesting that the peptide substrate slips in the absence of 
sufficient bonds to hold the carboxy group firmly in place (Kim et aI., 2003). 
Lisinopril binds to AnCE with a Ki of 18nM (cf. lisinopril-binding to tACE: 
Kj=0.2nM) (Williams et a!., 1996; Kim et aI., 2003). There is a similar penta-
coordination found in this complex as in the enalaprilat complex, with the two 
oxygens of the carboxylic group coordinating zinc with the active site histidines 
and glutamate. The phenyl group is extended towards the N-terminal lid of the 
enzyme, and interestingly occurs close (3.78 A) to an arginine residue (which 
was expected to be glycine, based on the enzyme sequence). This non-ideal 
association may partly explain the reduced lisinopril affinity of AnCE compared to 
tACE. The same main chain coordination occurs with Iysyl in lisinopril as with 
alanyl in enalaprilat. The lysine side chain has water-mediated hydrogen bonds 











0 36°, 0 146 and E150. These correspond to E376, E162 and T166 in tACE (Fig. 1-5), 
and are thus conservative changes. 
Interestingly, though V3SO is usually considered to playa role in the binding of the 
substrate via the 52' pocket, it appears that the side chain may have freedom to 
swing round to form part of the 51' pocket (Fig. 1-8). 
1.3.4.2. ACE2 (Homo sapiens) 
The ACE2 protein is a human homologue of ACE that has been found to playa 
crucial role in the regulation of heart function (Crackower et aI., 2002; Oanilczyk 
et aI., 2003; Oudit et aI., 2003). The ACE2 structure was determined in the 
absence and presence of a specific inhibitor, MLN-4760 «S,S}-2-{1-carboxy-2-[3-
(3,5-dichlorobenzyl)-3H-imidazol4-yl]-ethylamino}-4-methyIpentanoic acid) 
(Towler et aI., 2004). Like the tACE structure, the nzyme can be divided into two 
sub-domains between which runs the deep cleft in which the substrate binds. In 
the case of ACE2, the substrate binds at the bottom of this cleft - the cleft does 
not run through the entire molecule length. The two structures suggested the 
occurrence of a Significant hinge-bending motion between the two subdomains 
on the binding of the inhibitor (or also, presumably, substrate). 
The absence of an apparent similar hinge-bending motion between the unbound 
and ligand-bound tACE (Natesh et ai., 2003) has been suggested to be an 
artifact of the experimental conditions of the crystallisation process. The native 
structure, determined using tACE with no substrate nor inhibitor, does not have 
an unoccupied active site: there appears to be an acetate molecule coordinated 
to the zinc, as well as an unknown molecule modelled as an N-carboxyalanine. 
These two molecules, bound in an orientation analogous to the inhibitor lisinopril, 
can be considered ligands of the native structure, and therefore preventing a true 











Figure 1-9, Alignment of tACIO and AClO2 showing how the 52' sile is occluded by R'" in 
ACI02_ The lACE aclive site surface is shown in whito/pale g'f:y. along with some active 
$ite res idues (lines , whllo C aloms , and lis inop.il (sticks. o.ange C atoms). AClO2 residues 
h .. o green C aloms. The clash ootween R'" and Ihe C_termin"1 carboxyl.1e ollisinopril 
indicates clear1y why lACE inhibitors ~ re i ".,ffccti.e against ACE2_ 
The ACE2 and lACE structures are readily superimposable {r,m s,d, = 1 80 A} 
(Towler et al , 2004)_ At the active site, many residues are conserved; however, 
there are significant differences some 01 which can be understood to contribute 
to the difference in function and specificity of the enzymes, For example, R'" in 
ACE2 stabitises the C-terminai carboxylate of the Inhibitor MLN-4i60 In the 51' 
poSition, This residue is replaced by a glutamine in lACE (Q2~\ whICh also 
coordinates the C-terminal carboxylate of substrate or inhibitor (at 52' of the 
enzyme) The much greater size of the arginine residue in ACE2 (compared to 
glutamine in tACE) means that the potential 82' pocket in ACE2 is ocduded. as 
shown in superimposition of lACE and ACE2 active sites (Fig 1-9) This offers a 











peptidyl dipeptidase cleavage by tACE (Crackower et aI., 2002; Dudit et at, 
2003). This change in the geometry of the 52' pocket also accounts for the 
ineffectiveness of tACE inhibitors against ACE2 (Tipnis et aI., 2000; Towler et aI., 
2004). 
1.3.5. In silico modelling structures 
1.3.5.1. Background 
Over the past three decades there have been rapid improvements in computer 
processing capacity and abilities to map chemical and conformational space. 
These have enabled the generation of reasonable models of enzymes and 
enzyme-inhibitor complexes based on experimentally determined structures and 
prior databases of chemical interactions and parameters. 
The conformations of inhibitors at the active site of ACE were predicted nearly 
two decades ago using available data from the structures of several known active 
inhibitors (Mayer et aI., 1987). Recently, it was shown that the active site model 
prediction was indeed highly accurate, when compared to the published ACE-
inhibitor complex structures (pdb codes 1086, 1 uze, 1 uzf - ACE-lisinopril, -
enalaprilat and -captopril, respectively). It was suggested to be the earliest 
example of such validation, and exemplified in support of the methodology of 
active site mapping using known active analogueslinhibitors. Active site mapping 
is a most useful approach in the absence of three-dimensional structural 
information about a protein target. If a set of inhibitors of sufficient chemical 
diversity has been characterised, then important geometric parameters of the 
active site can be accurately estimated. This is based on the assumption of the 
narrow geometric constraints present at active sites, enabling substrates to be 
held in particular conformation for catalysis (Kuster & Marshall, 2005). 
The development of numerous software applications specific to biological 
macromolecules has resulted in the rapid growth and progress of the field of 











alignment of protein domains with high homology (Chenna et aI., 2003) (Fig. 1-5). 
Software applications such as MODELER (Sali & Blundell, 1993) or CHARMM 
(Brooks et aI., 1983), can be used to construct models of the sample protein 
based on its sequence and determined similarity to a template. In the case of 
docking of small molecules - typically inhibitors - there are many software suites, 
such as AutoDock (Goodsell et aI., 1996) and ZDOCK (Chen et aI., 2003), that 
facilitate (amongst other things) the creation, and docking of molecules into 
macromolecules, and subsequent refinement of the interaction between them. 
1.3.5.2. ACE .. inhibitor docking and modelling 
Various docking software suites have been employed to support or rationalise 
experimentally determined inhibition data, or to motivate for the modification of 
well-established inhibitors in order to promote domain selectivity. In this quest the 
Accelrys package INSIGHT II (Accelrys, San Diego CA, USA) has been used 
successfully in our laboratory in modelling the conformations of various inhibitors 
bound to the active sites of ACE (Nchinda et aI., 2006a, 2006b). Other groups 
have used CHARMM (Brooks et aI., 1983) to surmise about the interactions of 
the C-domain selective RXPA380 with ACE (Georgiadis et aI., 2004) and 
MODELER (Sali & Blundell, 1993; Marti-Renom et aI., 2000) to achieve results 
that have provided molecular insights into the determinants of selectivity in the 
binding of a range of current and potential clinical inhibitors of ACE (Tzakos & 
Gerothanassis, 2005). 
1.3.5.3. ACE N-domain docking and modelling 
The model of ACE N-domain bound to iisinopril indicated a similar binding 
structure for the two ACE domains (Fernandez. et aL, 2003). The z.inc ion is 
penta-coordinated to the conserved active-site histidines and glutamate, as well 
as the carboxylate oxygens of the inhibitor or substrate. The glutamate residue 











according to Corradi et al. (2006» plays a role in coordinating the catalytically 
important water molecule (water385), as well as the lisinopril carboxylate. 
As in the C-domain crystal structures, the P1 phenyl group interacts via aromatic 
stacking with the side chain of F490 (corresponding to F512 in tACE). The Iysyl 
main chain amine binds the carbonyl of an alanine residue; the prolyl side chain 
fits easily in the large hydrophobic 82' pocket, while its carboxylate is coordinated 
to K489 (K511) and y498 (y520). The major differences occur in the binding of the 
Iysyl side chain, where the 0 377 and E162 of tACE are replaced by Q355, 0 354 and 
0 140 (Fig. 1-8). The distance between Iysyl and side chains is greater, so these 
interactions are likely water-mediated (Fernandez et aI., 2003). 
From their structure, Tzakos et al. (2003) also speculated that a series of 
significant residue changes in the 81 and particularly 8 l' pockets may contribute 
significantly to the substrate and inhibitor specificities. In addition they found a 
more positively charged binding groove for N-domain, based on surface potential 
calculations. 
1.3.5.4. C-domain ACE-inhibitor models 
Although the crystallisation and structure determination of ACE complexed with 
three inhibitors has been demonstrated, it has so far proved to be a difficult 
procedure to reproduce. It must also be noted that at least 17 ACE inhibitors 
have been approved for clinical use (Zaman et aI., 2002). Therefore details of the 
mode of binding have only been elucidated for a small fraction of commercially 
available inhibitors. It is expected that such detailed information would be 
particularly useful in the modification of current inhibitors in the quest to obtain 
domain-selective inhibitors - it would allow the delineation of the factors to be 
exploited in order to attain domain selectivity. Understanding these factors can 
guide the design of second-generation domain-selective inhibitors. 
With this in mind, Tzakos and Gerothanassis (2005) have determined the binding 











N~domain (generated using MODELER). The results for the calculated complex 
of C~domain ACE and lisinopril agreed well with the experimentally determined 
structure, giving credence to the results for the other docked structures. 
1.4. Rationale of the Study 
1.4.1. Domain-selective inhibition 
Most commercially available inhibitors were designed before the discovery of the 
two domains, and have turned out to be efficient at inhibiting both domains to 
roughly similar extents. 
Since the discovery of the two domains of ACE, studies that have strongly 
suggested that C-domain inhibition is both necessary and sufficient to produce 
an anti-hypertensive effect have encouraged investigations into the development 
of C-domain selective inhibitors. For example, Bernstein and others have shown 
in mice that the N-domain alone cannot restore low blood pressure to normal 
levels (Esther et ai., 1997), while the administration of an N-domain specific 
inhibitor, RXP407, had little effect on angiotensin hydrolysis by sACE (Dive et a!., 
1999; Junot et aI., 2001). Furthermore, C-domain-selective inhibition will allow 
BK degradation by N-domain, preventing BK accumulation seen in angioedema. 
Finally, because BK potentiation via B2 receptor resensitisation is highest when 
both domains are inhibited, an inhibitor targeting the C-domain may have a lower 
proclivity for excessive BK stimulation (Acharya et at., 2003). 
1.4.2. Structural determinants of selectivity 
The Iysyl side chain of lisinopril makes contact with acidic residues in the S1' 
pocket. The S l' pocket does not appear to be of major importance for domain 
selectivity, for the following reasons. Usinopril is roughly equally effective against 
both domains. In addition, the S1' residues are moderately conserved between 











developed with special consideration given to 52' pocket-based (C-domain) 
selectivity (Acharya et aI., 2003; Georgiadis et aI., 2004). Trandolaprilat, whose 
design (before the discovery of the two-domain nature of ACE) was based on 
enalaprilat, also has a bulky aromatic group (indole ring) at its P2' position, and 
this inhibitor was also found to be moderately C-domain selective (Wei et aI., 
1992). 
The inhibitor RXP407 demonstrated a 1000-fold selectivity for the N-domain, 
while RXPA380 has shown a 3300-fold selectivity for the C-domain (Dive et aI., 
1999; Junot et aI., 2001; Georgiadis et aI., 2003; Georgiadis et aI., 2004). 
The remarkable selectivity of RXPA380 seems to have its basis in the 
interactions with the enzyme that occur in the P2' p sition, occupied by a 
tryptophan residue (Fig. 1-10). Mere replacement of the tryptophan side chain 
with a methyl group or pseudo-arginine (to form the analogue Compounds 8 and 
11, respectively) reduced selectivity in both cases from 3300-fold to 22-fold, fully 
two orders of magnitude. The analogue Compound 9, with methyl groups at both 
P1' and P2', despite showing high affinity for ACE, exhibits no selectivity 
whatsoever. Furthermore, the carb xybenzyl moiety that occupies the 52 pocket 
of the enzyme appears important for binding, but does not seem to playa direct 
role in the selectivity of the inhibitor, as modifications of inhibitor structure at the 
P1' and P2' positions appear sufficient to eliminate or enhance C-domain 











Figure 1-10. Prediction of 52' pocket configuration by Georgiadis ,,( al. Of the 12 residues 
predicted to be within 5 A of RXPA380 tryptophan side ch~in, 0'" and F'''' are not shown_ 
K'" i~ 5hown for d~rity(Gcorgiadi~ ct al., 2004)_ 
Modeiling of RXPA330 docked into the active site of tACE-lisinopril structure 
(replacing lismopri l) has suggested that the Interactions 01 the tryptoph"n at P2' 
are specifically criticat to setectivity The lysine residue at P1' in Iisinooril of the 
tACE-lismopril structure (108a) has been found to have unusual phi and psi 
angles that are m fact tYPIcal fOI a prolme residue. This observation is suppclrled 
by the ease with which the pseudo-prcXine at Pl' in RXPA380 ,s modelled - the 
two fesidues correspond closely The interactions of the pseudo-proline are with 
AJ >< and H" ", which come from a rnghly conserved region of ACE, and therefore 
it appears that these interactions cannot explain domain selectivity 
On the other hand. of twelve resldlies defined by Georgiadis et al (2004) as 











The major differences are the replacements of hydrophobic valines V379 and V380 
by serine and threonine, respectively, and the conversion of acidic residues -
E376D and D453E. These changes may sterically interrupt the possible H-bond 
interaction between the nitrogen of the indole ring of the P2' tryptophan and the 
0 453 carboxylate in tACE. 
1.4.3. Project Aims 
Although these findings provide some explanations, further structural data are 
required in order to gain definitive insights into the interactions mediating such 
selectivity, and these data may even point to mechanisms associated with the 
selectivity. There are at least two currently tractable ways to achieve these 
insights: co-crystallisation of RXPA380 with tACE or the C-domain of ACE, or 
structural determination of a tACE [C-domain] mutant containing N-domain 
residues in the key pOSitions, preferably co-crystallised with lisinopril or 
RXPA380. We have adopted the former approach, and expect this to shed light 
on the factors determining selectivity in the C-domain. 
Therefore the aims of this project are: 
1. Determination of the conditions that are conducive to the production of 
diffraction-quality and -size crystals of minimally glycosylated tACE-
inhibitor complexes; 
2. Co-crystallisation of tACE with the C-domain-selective inhibitor RXPA380, 
X-ray diffraction data collection, and solution and refinement of the 
structure of tACE complexed with RXPA380; 
3. Modelling in silico of the tACE-RXPA380 interaction for comparison of the 






















2.1. Protein expression 
Testis ACE (tACE) mutants with reduced glycosylation were previously 
produced by site-directed mutagenesis and stably transfected into Chinese 
Hamster Ovary (CHO) cells (Gordon et aI., 2003). The mutants used in this 
work were the tACE-g13 and tACE-g3 mutants, which have only two (1 st and 
3rd) and one (3fd) glycosylation sequons intact, respectively. CHO cells were 
cultured in medium composed of equal amounts of Dulbecco's Modified Eagle 
Medium (DMEM) and Ham's F12 (Highveld Biological, lyndhurst, RSA), 2% 
foetal calf serum (Gibco BRl, life Technologies, UK), and 0.02M HEPES as 
described previously (Ehlers et aI., 1991a). The medium was harvested at -3 
day intervals for 14-16 days after the first induction with ZnCI2. After the first 
two passages with 2% FCS medium some of the T150 flasks were exposed to 
2% FCS medium containing the a-glucosidase I inhibitor N-
butyldeoxynojirimycin (NBDNJ). The bulk of the medium was stored at -20"C, 
with 1 ml aliquots removed in order to carry out ACE activity assays. 
2.2. Purification by affinity chromatography 
Medium containing tACE-g13 mutant protein was passed over a lisinopril-
Sepharose affinity column at a rate of 1.1 mUmin using a Gilson Minipuls2 
pump (Villiers-Ie-Bel, France). The entire flow-through was retained and 
assayed for ACE activity. The column was washed overnight with wash buffer 
(20 mM Hepes, pH 7.5 containing 0.3 M NaCI) and eluted with 50 mM sodium 
borate (pH 9.5). An in-line spectrometer (D-Star Instruments, VA, USA) 
measured absorbance of the eluted fractions at a wavelength of 280 nm. 
2.3. Enzyme activity assays 
The eluted fractions were pooled and dialysed against 5 mM HEPES pH 7.5 
containing protease inhibitor (0.1 mM PMSF, Roche Diag. GmBH, Germany) 











The enzyme activity of the dialysate was measured using hippuryl-histidyl 
leucine (HHl) as substrate (Friedland & Silverstein, 1976). Briefly, dialysate 
aliquots were incubated at 37°C for 15 minutes with the substrate HHl. The 
reaction was stopped by placing the tubes on ice and adding 750 J,Jl of 0.28 M 
NaOH. 50 J,Jl of 8 mM o-phthaldialdehyde was added, and the sample was 
left for 10 min to allow formation of the fluorescent adduct from the reaction 
between the o-phthaldialdehyde and the primary amine of the histidyl moiety 
of Hl that results from ACE activity. 
The dialysate (or aliquot of each fraction, or of harvested medium) was diluted 
appropriately so that the fluorescence reading would fall within the acceptable 
detection range. In the case of the medium activity assays, five- or ten-fold 
dilutions were carried out in order to minimise the effect of quenching of the 
fluorescence signal due to the presence of many other proteins and other 
organic material in the harvested medium samples. 
2.4. Protein concentration 
A 4ml volume ultracentrifuge tube (Milii pore , MA, USA) was washed with 
5mM HEPES. The dialysate was placed into the tube over the filter, and 
centrifuged at 4500 lie 9 until the desired concentration was reached. The 
protein content was determined using a standard Bradford assay (BioRad 
laboratories GmbH, Germany). The concentrated ACE was stored at 4°C. To 
check the purity of the concentrated enzyme, between 3 J,Jg and 20 J,Jg of the 
sample was electrophoresed on 10% SOS-PAGE. 
2.5. Crystallisation 
2.5.1. General crystallisation conditions 
Crystallisation (or reservoir) buffer was prepared as done previously (Gordon 
et aI., 2003; Watermeyer et aI., 2006). The buffer solution consisted of 15% 











hydrated sodium acetate (Merck, Darmstadt, Germany), and 10 IJM hydrated 
zinc sulphate. The pH of the buffer was adjusted to between 4.4 and 5.0 with 
HCI and NaOH using a Beckman pH machine (Beckman, Irvine CA, USA). 
The buffer was filter-sterilised (0.22 IJm filter) and stored at 4"C. 
Typically, drops of volume 4 IJl were placed onto each cover slip (2 IJl protein 
or (protein + inhibitor) mixed into 2 IJl reservoir buffer) and inverted over a 1 
ml reservoir buffer volume (the hanging drop method). This was optionally 
overlaid with 0.5 ml of a 1:1 mixture of silicon:paraffin oils (Hampton 
Research, Aliso Viejo CA, USA). 
Crystallisation trials were set up at an ambient temperature of 18-21 "C in an 
attempt to minimise condensation on the cover slips. Plates were placed in a 
low-temperature incubator (United Scientific, Cape Town, RSA) at 16"C, atop 
three layers of packing foam (-4 cm total thickness) in order to minimise 
interference with crystal formation by vibrations of the incubator. 
2.5.2. Initial tACE-g13-RXPA380 co-crystallisation 
conditions 
The range of inhibitor concentrations used initially was such that a final (in-
drop) concentration of between 3 nM and 1 IJM was used in the crystallisation 
trials. The final in-drop protein concentration was either -0.75 mg/ml or -1.65 
mg/ml, which correspond to approximately 10.51JM and 231JM, respectively. 
2.5.3. Final tACE-g13-RXPA380 co-crystallisation 
conditions 
Crystals of native tACE-g13 (the original in-drop concentration was 1.65 
mg/ml) were dissolved by transferring the cover slip to a well containing only 
distilled water. After 24 hours, 1 IJl of 0.46 mM RXPA380 was added to the 4 











inhibitor. The cover slip was then re-transferred to the well containing the 
appropriate reservoir buffer, as before. 
2.6. Data collection and processing 
Crystals were visually inspected for quality, and their dimensions were 
measured using an in-lens graticule on a stereomicroscope (Leica 
Microsystems, Wetzlar, Germany). Images were acquired on a Leica Z16 
APO (KLl500 LCD) stereomicroscope connected to a computer, using the 
IM500 program (Leica Microsystems, Wetzlar, Germany). 
2.6.1. In-house data collection and processing 
Preliminary diffraction data from the best crystal produced using the initial co-
crystallisation conditions were collected on the in-house X-ray diffraction 
machine at the University of Western Cape, South Africa. The X-ray diffraction 
machine consists of a Rigaku RUH3R copper rotating-anode X-ray source 
operated at 40 kV, 22 rnA; a Rigaku R-axis IV+ image plate camera (Rigaku 
MSC, Tokyo, Japan); an X-stream 2000 low-temperature system (Rigaku 
MSC, Houston TX, USA); and an AXCO PX50 glass capillary optic with a 0.1 
mm focus (Australian X-Ray Capillary Optics, Parkville VIC, Australia). 
Images were collected between 00 and 1800 , with an oscillation angle of 0.5 0 
per frame, to make a total of 360 data frames. The exposure time for each 
frame was 600 s. The detector-to-crystal distance was set at 100 mm, and 
later refined to 102 mm. 
The image frames collected were indexed and integrated with Denzo and 
scaled and merged with SCALEPACK (Otwinowski & Minor, 1997). Molecular 
replacement using EPMR v2.5 (Kissinger et aI., 1999) and the structure of 











to obtain an initial model with phases. Data in the resolution range 15 - 4 A 
were used in the evolutionary search procedure. 
Model refinement was carried out using input scripts (modified as required) of 
the Crystallography and NMR System (CNS) v1. 1 (Brunger et aI., 1998). 
2.6.2. Synchrotron data collection and processing 
Testis ACE-g13-RXPA380 co-crystals, produced using the final 00-
crystallisation conditions, were transported in trays to the European 
Synchrotron Radiation Facility (ESRF) at Grenoble, France. The crystals were 
observed again under a microscope to ensure that there had been no loss or 
damage in transit. The selected crystal was picked and soaked briefly in a 
mixture containing 80% reservoir buffer and 20% glycerol, acting as 
cryoprotectant. Each crystal was then placed in a special labelled vial 
containing liquid nitrogen. Ten of these vials were slotted into a cartridge (or 
"puck") for storing the crystals within the microdiffractometer. 
Diffraction data were collected on the BM14-UK beamline at ESRF, using 
radiation of wavelength of 1.033 A with maximum intensity of -7.5 x 1011 
photons. The beam had a focal area of 0.25 mm2 . Diffraction images were 
recorded on the MARMOSAIC225 charge-coupled detector, and had an area 
of 225 mm x 225 mm. Images were collected between 0" and 144" with an 
oscillation angle of 1.0" per frame, to make a total of 144 data frames. The 
exposure time for each frame was 40 s. The detector distance was set at 
193.8 mm. 
The image frames collected were indexed, integrated, scaled and merged 
with HKl2000 (Otwinowski & Minor, 1997). Molecular replacement using 
EPMR v2.5 (Kissinger et aI., 1999) was carried out to obtain an initial model 
with phases. The structure of native tACE-g13 (Watermeyer et aI., 2006) was 
used as a starting model. Data in the resolution range 15 - 4 A were used in 











2.7. Structure refinement 
Model refinement was carried out using input scripts (modified as required) of 
CNS v1.1 (Brunger et al., 1998). An initial 8-factor correction was employed in 
each refinement round, with a low-resolution limit of 6.0 A. A general bulk 
solvent correction was also automatically determined and used. Coordinate 
minimisation was carried out using a maximum likelihood target with structure 
factor amplitudes. A relative weighting for the X-ray term was automatically 
determined and applied. An automatic weighting term was also applied during 
8-factor minimisation. 
Difference FObS -Fcalc and 2Foos -Fca/c maps were calculated using coefficients 
calculated from sigmaa weighting. A test set of 776 reflections (3.7% of the 
total) was excluded from all refinements, and was used to calculate the RfnIe 
statistic. Inspection of maps and models and model building was all carried 
out in 0 (v10.0)(Jones et aI., 1990). 
After the first round of refinement, the program Mapman (Kleywegt & Jones, 
1996) was used to locate the zinc and chloride ion peaks. These locations 
were confirmed by inspection in 0. Group 8-factors were refined (with each 
residue treated as two parts, main chain and side chain). Water molecules 
were added gradually to the model with Mapman and generally searching for 
peaks above 40 in the FObS -FC8/C map. These were confirmed or added to 
using the CNS script water-pick.inp, and checked in 0, by ensuring that 
reasonable hydrogen bond donors and acceptors were available to the 
putative waters. In later rounds of refinement some peaks above 30 and 2.50 
were also used. 
In order to obtain coordinates for the glycan residues, a Co-alignment of the 
model to a complete native tACE-g13 structure was made. Glycan residues at 
N72 (g1, one glycan) and N109 (g3, up to five glycans) were then adjusted to fit 
the observable difference density. Later on in refinement, the glycan at N 72 











because of unclear density and very high B-factors suggesting only partial 
occupancy or a high degree of flexibility. 
The inhibitor RXPA380 (Georgiadis et aI., 2004) was built from the available 
chemical structure and stereochemical details using the ProDRG server 
(Schuttelkopf & van Aalten, 2004). The server also generated the molecule's 
topology and parameter files for use in CNS, and minimised the structure for 
the first manual "docking" into the active site. The minimised structure was 
then manually placed into the active site using tools in O. Permitted torsion 
angles of the molecule were adjusted in order to fit the electron density as 
seen in the difference map. 
In subsequent model building the cis- and trans- conformations of the peptide 
bonds were checked, although the peptide torsion angles were not altered. 
The inhibitor was fitted until no positive peaks above 1.80' in the Fobs -Fca/c 
map remained, and no significant negative density peaks (indicating atoms in 
the model not accounted for by the density map) were discernible. 
The cycles of refinement were concluded when they resulted in no further 
substantial improvements in the map phasing and no further decrease in both 
the Rfree and Rcryst. 
2.8. Structure validation and analysis 
The MolProbity server was used to switch asparagine, glutamine and histidine 
side chains by 1800 where the analysis of nearby contacts and hydrogen 
bonding network supported such a switch (Davis et al., 2004). 
Ramachandran, rotamer and CI3 plots were also generated and checked. 
PROCHECK was used to generate Ramachandran plots and other 
stereochemical plots that give indication of the quality of the model 
(laskowski et al., 1993). 
Alignments of the ACE-RXPA380 model with previously determined structures 











The CASTp server was used to calculate the volume of the active site cavity 
in tACE-g13-RXPA380 with a probe size of 2.5 A (Binkowski et aI., 2003). 
This was compared with the N-domain structure. 
2.9. Modelling: Docking and molecular dynamics of 
RXPA380 in active site of tACE 
Files of the testis ACE complexed with lisinopril (1086.pdb) and of the N-
domain complexed with lisinopril (2cSn.pdb) were used as the starting pOints. 
These were accessed and processed on a Silicon Graphics (SG) Octane 
workstation (Silicon Graphics, Mountain View, CA, USA) using INSIGHT II 
version 2000 (Accelrys, San Diego, CA, USA). 
Files were prepared for cycles of energy minimisation and dynamics by 
appropriate adjustment using the Builder module of INSIGHT II. Atom 
hybridisation and potential values were set appropriately. The consistent 
valence force field (CVFF, filename cvff.frc) was applied. Because INSIGHT II 
is not set up to recognise and incorporate the Zn2+ in its calculations, an 
appropriate substitute ion was chosen - Mg2+. In order to fix its position, the 
active site cation was bonded to the coordinating histidines, H383 and H387. 
The phosphinate inhibitor RXPA380 (Dive et aI., 1999; Dive et aI., 2004) was 
built into the active site with lisinopril as the starting template and using the 
INSIGHT II Builder module. Measure functions in the Viewer module were 
used to identify probable steric clashes between new inhibitor structures and 
the protein. The inhibitor moieties were then manually adjusted so as to be in 
as sterically favorable orientations as possible. 
The inhibitor and metalloprotease were combined into a single assembly for 
the molecular modelling steps. The Discover _3 module was used for all 












.. 2000 steps of Polak-Ribiere conjugate gradient minimisation 
.. 2000 cycles of molecular dynamics using Velocity-Verlet integration 
method (time-step :::: 1 fs) 
.. Compilation of a history of the configurations at an interval of 10 cycles, 
i.e. 200 frames 
III Determination of average conformation from history trajectory; 
III 3000 steps of Polak-Ribiere conjugate gradient minimisation applied to 
this average conformation. 
All experiments were carried out at constant volume (NVT) , at a constant 
temperature of 300 K, with a dielectric constant of 1, and in vacuo. Water 
molecules were also excluded. The non-bonded cut-off for molecular 
dynamics was 9.5 A (Nchinda et aI., 2006a, 2006b). 
The output conformation was written out to a pdb file for further analysis. 
Ramachandran plots were drawn using MolProbity (Davis et aI., 2004) and 
PROCHECK (laskowski et aI., 1993). To aid with evaluation, these were 
compared to corresponding analyses of tACE-lisinopril (pdb code 1086) and 
ACE N-domain-lisinopril (2cSn) (for C- and N-domains, respectively). An aI/-
molecule Caalignment to the ACE C-domain (1086) was then carried out and 
a r.m.s.d. value was calculated. An active-site alignment, using the 20 active 
site residues within 5 A of lisinopril in the PDB structure, was also carried out 
in order to provide a comparable illustration of the inhibitors bound in the 
active site. All alignments and molecular figures were generated using PyMOl 
(Delano, 2002). 
The key residues surrounding the inhibitor side chain groups at each subsite 






















3.1. Protein expression & purification 
Medium harvested from tACE·g13 and tACE-g3 CHO cells was assayed 
using HHl as substrale. The specific activity of Ihe rnedium was 142 mUlml 
(iolal vollJme = 340 ml ) and 89 mU/ml (total v~ume = 450 ml) for tACE-g13 
arod tACE-g3 respectively (1 mU defined as 1 nmol Hl produced per minute) 
tACE-g13 and tACE-g3 were purified from culture medium using a lisinopril· 
Sepharose c~unlll. The pre-column and post-column aliquots were assayed 
in order to determine ACE yields. For both lACE-g3 and tACE-g13 the yields 








Figure 3_1 . 10'1. 50S_PAGE showing effect of remov31 of glycosyl3lion 5ites from lACE. 
Between 10 and 20 ~g of prote in was loaded per lane. Marker lane (M) molecular 
w e;gh15 ore;n ko... Lones 1_2: 10 ~g and 15 ~g tACE-g3, ,~spectively. Lanes 3-5: 20 ~g 
per lane of different prepar~tions of IACE-g13. Lone 6: 20 ~g fully glycosyloted lACE. 
The fain! bands below the major bands collectively comprised less thon 5% of the 
protein loaded per lane. 
The protelrl concen(ra tiorlS of the pos(-c~umn fractions after dialysis were 
0. 158 mg/llli (total of 1 42 mg) and 0 191 mglml (total of 1.20 Illg) for tACE-











protein had a molecular weight of 72 kOa (Fig. 3-1, lanes 3-5) which was 
slightly lower than the fully gycosylated tACE (Fig. 3-1, lane 6). The tACE-g3 
protein bands (Fig. 3-1, lanes 1 & 2) also ran lower than the fully glycosylated 
tACE band, indicating similarly reduced glycosylation as expected. Minor 
proteins comprised :5:5% of the total protein. The tACE protein recovered in 
dialysate after pUrification gave a final yield of 4.2 mg/L and 2.7 mg/L for 
tACE-g13 and tACE-g3, respectively. 
3.2. Crystallisation 
Initial parameters for crystallisation conditions were obtained from previous 
work successfully carried out on tACE-g13 (Gordon et aI., 2003; Watermeyer 
et al., 2006). 
3.2.1. Crystallisation oftACE-g3 
Aliquots of tACE-g3 were concentrated to 2.0 mg/mL and 4.2 mg/mL, as 
determined by Bradford assays. The final concentration of tACE-g3 in the 
drop was 2.1 mg/mL. Clusters of needles, or alternatively, microcrystal 
showers were obtained (Fig. 3-2). Seeding was found to be a promising 
approach for increasing the size of tACE-g3 crystals; however, these 
experiments failed to yield diffraction quality crystals. 
3.2.2. Initial co-crystallisation of tACE-g13-RXPA380 
complex 
Aliquots of tACE-g13 were concentrated to various extents, from 0.5 mg/mL to 
6.6 mg/mL, as determined by Bradford assays. Production of native tACE-g13 
diffraction-size crystals was achieved with final (Le., in-drop) protein 
concentrations ranging from -0.25 mg/mL to 3.3 mg/mL. Crystals appeared 
gradually between 2 and 7 days after screens were set up. A fine preCipitate 
was conSistently observed to form before any crystals and remained after 











Figure 3-2. Microcrystals of tACE-g3 (1.4mgfmL) together with a considerable amount 
of prccipitato. Scale bar indicate s 0.2 mm. 
A 1.6 mglmL final concentration of protein (23 ~M) was used for the enzyme-
inhibitor co-crystall isation screens Inhibitor concentrations varied from 3 nM 
(the K; value for RXPA380) to 1 ~M (a 333-f~d excess of the inhibitor). T~ 
largest crystals were typicaijy about 0.35 mm ~ 004 mm in the visible 
dimensions. 
3.2.3. Final co-crystallisation oftACE-g13-RXPA380 
complex 
Th., concentration of the inilibitor in th., co-incubation was inu.,ased There is 
precedent for this approach - the co -crystals of tACELl.36NJ with lisinopril 
(-1 80 jJM) and with enalaprilat (10 mM) and captopril (10 mM) used for 
stnJctural determination all had excesses of inhibitor at least five orders of 
magnitude higher than their inhibition constants U,atesh et aL 2003; Natesh 













figure 3-3. Re-cry. tall isalion 01 IACE_gI3 crystals in presence of RXPA380, A. tACE_ 
913 nail .... cry~t~ls_ B_ The crystals had dissolved 48 hour. after .... placing .eseNoi, 
buff~r with water. C. Within four days of the addition of 4S0~M RXPA380 ~nd 
replacement of w;>ter with the regul ar re~"rvoir buffer ~15'Yo PEG400Q, ~OmM Na-
ac .. tale, 10~M Zn-sulphale), cry~tals had re-formed, D. M;>gnification of quadrant of 
cryslail;ulion drop (from C). Substantial precipit;>\& is easily observed along with well-











The concentration of RXPA380 used in the enzyme-inhibitor incubation was 
therefore increased to give a final in-drop concentration of 92 IJM, which is a 
-30700·fold excess relative to the Ki value, and an inhibitor-enzyme molar 
ratio of 4:1. This was achieved by dissolution and re-crystallisation of native 
protein crystals in the presence of 0.46 mM RXPA380. This approach was 
used, rather than using fresh protein sample, as this protein was clearly 
amenable to crystallisation. Soaking was not used as it is thought that 
substratelinhibitor access occurs via a conformational change (by hinge 
movement) that is both masked and prevented by crystallisation, so that 
inhibitor may not have access to the active site after crystallisation (Towler et 
al., 2004; Watermeyer et aI., 2006). The crystals produced were noticeably 
smaller than the original crystals, with dimensions of approximately 0.2 mm x 
0.02 mm for the largest crystals (Fig. 3-3). 
3.3. Data collection and processing 
3.3.1. In-house data collection and processing 
In total 424220 diffraction spots were recorded, and these data were indexed, 
integrated, scaled and merged with Denzo and SCAlEPACK programs 
(Otwinowski & Minor, 1997) to yield 104529 reflections to 2.8 A. 17739 unique 
reflections were obtained, with Rsymm ::: 26.1 %, I/o ::: 3.4, mosaicity ::: 0.68. 
The structure was solved using molecular replacement with EPMR v2.5 
(Kissinger et a!., 1999), with a correlation coefficient of 0.713 and R-value of 
0.575. A view of the initial Fourier difference FObS - Fca1c map gave no 
discernible evidence for the presence of the inhibitor bound to the tACE active 











3.3.2. Synchrotron data collection and processing 
After two months of storage in crystallisation trays at 16°C the crystals were 
transported to the European Synchrotron Radiation Facility (ESRF) at 
Grenoble, France. 
_._ .... _ ............ ymg statistics by resolution shells. 
Lower Upper Redund.1I Intens.a 0(1) 1/ 0(1) x'2 Rsymm (%) No. refl. II 
50.00 5.81 5.4 243.0 9.5 25.6 0.61 4.7 2113 
5.81 4.62 5.7 196.2 11.7 16.8 0.69 8.9 2000 
4.62 4.03 5.7 223.1 15.5 14.4 0.91 12.2 1993 
4.03 3.66 5.1 252.2 23.6 10.7 1.47 18.1 1931 
3.66 3.40 4.8 165.8 25.6 6.5 1.14 23.1 1678 
3.40 3.20 5.7 108.0 17.3 6.2 0.71 25.8 1959 
3.20 3.04 5.6 80.4 17.1 4.7 0.70 32.4 1949 
3.04 2.91 5.5 59.4 17.0 3.5 0.68 42.7 1931 
2.91 2.80 5.4 48.1 16.5 2.9 0.70 50.7 1940 
2.80 2.70 5.2 31.6 13.7 2.3 0.71 61.3 1929 
All shells (50-2.7) 5.4 141.7 16.5 8.6 0.82 18.3 19423 
a Redund. ::::: Data redundancy; Intens. :::: Signal intenSity; No. ref!. :::: Number of reflections 
Altogether 144 diffraction images were collected, each to a resolution limit of 2 
A (Fig. 3-4). A total of 525398 diffraction spots to 2.7 A were indexed, 
integrated and scaled to 105024 reflections. The symmetry-related reflections 
were merged. to give a total of 19423 unique reflections. The two major 
quality measures, I/o (8.6), and Rsymm (18.3%), were satisfactory for the set of 
reflections. In particular the 110 ratio, although being somewhat low for 
expected signal-to-noise ratios in crystallographic datasets, was considerably 
higher than the corresponding figure for the P212121 space group's systematic 
absences (110 ::: 0.16). Although the outermost shell (2.8-2.7 A) had Rsymm :::: 
61.3%, these data were included on the basis of high completeness (99.2% -
although HKL programs do not reject observations (Gewirth & Majewski, 
2003); Table 3), good redundancy (5.2) and acceptable signal-io-noise (2.3) 
ratios. The X2 value (0.82) for the set of reflections is somewhat lower than 
unity, the ideal value, so the error model should have been adjusted during 











even a deviation of 20% from 10 for i represents just a 10% aajustment in a 
which is acceptable (Gewirth & Majewski 2003). The data collection statistics 
by resoltitlon shells are shown in Table 2 
j 
---~~ 
Figure 3-4. Diffr~ction im~ga collacted for tACE-913-RXPA380 co-crystllis at BM14.UK, 
ESRF. 
The dark rings are due to Ice and perhaps frost on the surface of the crystals 
(Glaeser et al. 2(00) Due to the particularly dark innermost ring the 
reflections col!ected in the range 3.6-3.4 A were fewer, and so the redundancy 
of that shell was lower than al! the other shells (4.8 vs average 5.4: Table 2) 
However thiS redundancy still Indicated the co!lectioo 01 sufficient data in the 











Table 3. Crystallographic data statistics. Values in parentheses refer to the last shell 
(2.80-2.70 A). 
Diffraction data 




Total No. of reflections 
No. of unique reflections 



















aCompleteness data from HKL2000 include those reflections (2044. Le. 10.4%) which were 
subsequently found to have <I> SO. Taking these data into account, the final completeness 
figures were overall :::: 89.6%, outer shell ::: 81.3%. 
3.4. Structure soluti.on and refinement 
Molecular replacement using EPMR v2.5 (Kissinger et al., 1999) and a native 
tACE-g13 structure (Watermeyer et aL, 2006) as a starting model yielded a 
solution after just 2 cycles. The correlation coefficient was 0.693, with only 
one molecule in the asymmetric unit. 
The first B-factor correction was in effect the initial assignment of B-factors to 
the atoms, and this resulted in a significant decrease in the R-factors (Fig. 3-
6). 
After the first round of refinement (comprising a given number of cycles of 











6), the active site zinc and 2 chloride ions were located and added to the 
model. The sites of these ions were found at over 50 in the F"" - Fe,"" Fourier 
difference mdps Further model building arld refinemerlt led to the addition of 
the g!ycarl res!dues at N" and N"·, nvoughout the model building the glycan 
chain at Nl1 d!d not visibly exterld beyorod the first N-acetyl glucosamine 
linked to the asparagine dnd eventually even this was remo'.ed from the 
model At N' ~, however, several reSidues were ,.isible, arod most of these 
were retained in the final model. Waters were also gradually added as 
refinement proceeded Most of these were added after inspectiorl of the active 
site and subsequent modelling of the inhibitor. 
A 2F""s - Fco." composite omit mdp was calculated in order to reduce model 
bias. However this WdS found to be so similar to the 2Foo, - Fe"," that it gave 
esserltially the same mformation, and so its use was discontinued. 
Figure 3·5, Stereo representation of active sile of mod .. 1 with FO{Jc;", difl .. 'ence (f~" _ 
f , .... ) map conloured al 2.~(J level. before modeilino of lhe inhibitor. Thc zinc atom is 
shown as a sphe'e. 
After several rounds of refinement the F,~s - Fe"",, map of the active site was 
examined dt 2.50 (Figs 3-5, 3-6) This cledrly indicated continuous density 
suggesting a molecule coordinated to the zinc in an orientation similar to 
lismo[.lril and other inhibitors A crude alignment of a model of the RXPA380-











showed that the RXPA380 molecule could account completely for the as yet 
unassigned density. 
RXPA380 was successfully built with the correct stereochemistry and 
minimised using the ProDRG server (Schuttelkopf & van Aalten, 2004). This 
first structure was placed into the active site of the tACE-g13 model and 
adjusted, primarily by altering permitted torsion angles appropriately. Density 
for the pseudo-proline and the C-terminal tryptophan residue (particularly its 
side chain indole ring) could be seen very clearly between the zinc-
coordinating region (occupied by the phosphinyl group) and the known C-
terminus-coordinating residues K511 , Q281 and y520. On the other side (the pre-
scissile bond side) the relative pOSitions of phenyl ring and the carboxy benzyl 
group were easily distinguished by size, and fitted accordingly. After a round 
of refinement the overall position of the inhibitor was in accordance with the 
2Fobs - FC81c electron density. although the C-terminus (particularly the 
tryptophan indole ring) required further attention. 
Once the inhibitor model was built into the active site in a conformation that 
satisfied the constraints of the torsion bonds and the electron density, a final 
check of the model was carried out, with the addition of further water 
molecules and the modification of glycan residues and the side chains of 
other residues. In total 109 water molecules were included. A last round of 
restrained refinement saw the Rcryst and Rfree values drop to 23.69% and 
27.97%, respectively (Fig. 3-6). This improvement in phasing did not lead to 
any significant alterations in the density maps to allow further improvement of 
the model, particularly at the glycan chains or the active site. The residues 
435-438 in a flexible loop and 618-623 at the C-terminus, for which 
continuous density could not be determined, even for the main chains, were 
truncated from the final model. This truncation resulted in slight increases in 
Rcryst to 23.70% and Rfree to 28.17%, since these residues were accounting for 
the observed data, however insufficiently. The data refinement statistics are 











Table 4. Refinementstatistics. 
Parameter 
Resolution range (outer shell) 
Rcryst (outer shell) % 
Rrree (outer shell) % 
No. of protein atoms 
No. of solvent atoms 
No. of inhibitor atoms 





Estimated coordinate error 
B-factors (A2) 
Overall mean B-factor 
Protein main chain B-factor 




Chloride atoms (CL 1, CL2) 
Ramachandran analysis 
Residues in favoured regions (%) 
Residues in allowed regions (%) 
Residues in disallowed regions (%) 
Value 





















Rcryst::: i:1I {IFObs\-lFcalcl} I i:II IFObs \, where FObs and Fcalc are the observed and 
calculated structure factor amplitudes of the reflection h. 
Rfree ::: i:1I {IFObs\-lFcsICI} I i:1I IFObS\. where FObs and FcaJc are as above, for a test set of 
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The side chains of three N, nine Q and three H amino acid residues were 
"flipped" by the MolProbity server (Davis et at., 2004), in order to improve the 
probable hydrogen-bonding network of the molecule. These flipped N 
residues did not include N72 or N109, as these are the sites of glycosylation, 
and have fixed side chain orientations. 
Table 5. Comparison of un it cell dimensions of tACE structures determined to date. 
Structure (pdb code) a (A) b (A) c (A) Unit cell volume (A'3) 
Native tACE (108a) 56.62 85.06 133.79 644345.8 
tACE-lisinopril (1086) 56.47 84.90 133.99 642388.7 
tACE-captopril (1 uti) 56.65 84.90 133.50 642079.6 
tACE-enalaprilat (1uze) 56.72 85.35 133.73 647393.9 
tACE-g13 a 59.81 84.90 135.99 690539.4 
tACE-g13-RXPA380 59.89 85.15 135.32 690060.2 
IiJ.M. Watermeyer (2004). 
3.5. Structure validation 
MolProbity C~ and rotamer plot checks revealed no structural anomalies 
requiring urgent attention (Davis et al., 2004). Ramachandran plots and other 
analyses indicated satisfactory geometry. A few outliers flagged in the 
MolProbity-generated Ramachandran plot were checked and adjusted 
accordingly. These included A354, whose carbonyl oxygen has been shown to 
coordinate the Iysyl amine nitrogen in the tACE-lisinopril complex (Natesh et 
aI., 2003). 
The final structure (after the truncations) was not minimised because the 
changes to which the penultimate model was subjected were collectively 
minor, and the Rfree value, in remaining constant or increasing with more 












Final Ramachandran plots from Mo!Probity (Davis ei a!, 2(04) and 
PROCHECK (Laskowski et al. . 1993) for this fInal adjusted model indicated 
that almost all resIdues had satIsfactory pili and PSI angles (FIg 3-7, Table 4). 
The only non-glycine exc.eptiO!l was A'19 which is marginally an outlier 
according to MolProbHy. This can be attributed to the fact mat this residue 
follows a proline in sequence and occurs effectively at the junction between 
loop and a-helix 4. 
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FigurQ 3_7. R~m~ch~nd'~n plots LQft· PROCHECK R~m.chand,"n plot of lin.1 model. 
Only a lew ~Iy";"" I'es ;.!ues (I'e ~f"se nte d lly tdangl esl, "'Q to be found;n the 
disallowed regions, shown in white. Right: MolProbity Ramachandr3n plot of fiMI 
model, excludiny ~lycine . nd proline residues. 
3.6. Structural analysis 
3.6.1. Overall structure oftACE-g13-RXPA380 complex 
Like other lACE structure:>, the present structure reveals a predominantly 
helical protein, elliptical in shape and containing a buried active site betweel1 
two sub-doma!ns The tACE-gn Imit cell is marginally larger than the 
tACElI36NJ from the dimensions of both the natIve structure aM this ligand-














Figure 3-8. St~reo view 01 final mod<llkld IXlsilion of RXPA380 (pur~le carbons, 
phosphorus in or~nlle) in tACE'p13 ;>clive site ~nd its m with experimental density 
m~p. The c~talytic tri~d (H'''. H" , 10'''115 $ hown in gmon I"'{)$. The .ioc ion and a C· 
lenninal carboxylate-coordinating waler are shown as metallic blue and red spheres, 
respe~tiv~ly, Density map is 2F "', - F" ... contoured at 1.3 (J, 
80th domains contribute residues to ttle active site (Natesh et al _ 2003) The 
a!igl1ment of tACE-g13-RXPA380 with (he other structures reveals almost 1"10 
difference between them (r,m,s_d. values = 024 A [tACE-llsll1Opnl], 0.26 A 
[tACE-enalaprilat], 0.26 A [lACE -Gaptaprill: Fig 3-9; Fig 3-14) 
Figure 3-9. Stereo diagram of all-C. alignment of lACE-inhibitor oomplexu ; 
tAC~b.36~J--<!nalapril (luze, purple), tACIOl!.36NJ-captoprii (luzf, b~e), tACEl!.36NJ-
lisinopril (1086 , yellow) and tACE.g1J.-RXPA380 Igreen), Innibitors ~re shown as sticks 
in corresponding colours, The zinc and chloride ions are shown as purple and hot pink 











- - '- -- _ _ •• r ... fi,..'" "'ad chloride binding 
Testis ACE-g13 has Intact g lyCOSyJalIVII ~"'<Y~"~ _ " , 
(g3) As with the previously determHled native tACE-g13, the extellt of 
glycosyiatioo that can be correlated with continuous eledron density from 
differellGe or omil maps is greater at N""' (Fig. 3-10). In this case. no density 
could be Interpreted evell for the ring portion of the first N-acetyi giucosamme 
residue linked to N,2 
Figur" 3_10. GlycMylation 01 tACE-g13-RXPA380 at N109, re~idues shown ~s slicks. 
DeMily m,p i~ 2Fo •• - Fn .... at 1.2", The penultimate residue jmannose), for whOch 
sulficienl difference density could not "" di~c~m"d, is r~"dQr~d as IinQ~_ 
The glycosylatioo at N '09 appears to De more extensive th~~ th(Jt which 
occurs at N" in tACE-g13 (Watermeyer et ai, 20(6). at least with respect to 











factors sufficiently low to al low their incorporation into the model The N72 
glycosylation site has beefl shown to occupy a larger water chaflnel than that 
taken up by N'"u which could explain the greater degree of order observed at 
the N' og site. This sole glycosylation site, alorlg with the rest of the tACE 
surface , is sufficieflt for intermolecular COfltacts that facilitate crystallisation 
(Watermeyer et al , 20(6) 
F;guro 3_11. ChloridQ b;ndir.g s ;t~s cf tACE-g13- RXPA380, A. CI site with "".ter 
ch~nneL The tryptoph~n residues making up the hydrophobic shell are shown as lines 
le)(cept the chloride ligarK! W"'''). 2F "", - F,."" density maps are contoured at 1.20. 
The chloride sites (Fig , 3-11) were easily discemibte, as they were tocated 
(together with the ziflC ion) as peaks above 5a in a FOllrier differeflCe map 
The 8-factors were refil1ed to 12.4 A2 and 184 A' for el' and CI", 
respectively. The bindirlg site of CI1 occurs withifl a hydrophobic shell of four 
tryplophal1 residues (W'/;l 21", . SO. <."\ one of which (W4B' ) is also a chloride 
ligand In addition. two arginine res idues , R' OO and R~a9 coordinate the 











molecule, could not be located with certainty at this resolution, although there 
is a water molecule 5 A away that seems to form the end of a system of water 
residues leading to the channel. 
At C12, the three ligands of the anion were side chains of R522 (Nt atom) and 
y224 (01'1 atom). The presence of a water channel from the milieu into the CI2 
site has been postulated by Tzakos and colleagues (2003), but strong 
evidence for this was not observed at the site. 
3.B.3. Binding ofRXPA380 to tACE-g13 
3.6.3.1. Overall 
RXPA380 has been shown to bind to the C-domain of ACE with a Ki of 3 nM, 
comparable with the most tightly binding inhibitors of ACE (Wei et aI., 1992; 
Georgiadis et aI., 2004). This inhibitor binds to tACE-g13 in an extended 
conformation with its central phosphinate group coordinated to the catalytic 
zinc (Fig. 3-8). Three residues, K511 , Q281 and y520, coordinate and stabilise 
the C-terminal carboxylate from 2.6, 3.0 and 3.8 A, respectively. A water 
molecule, wat11, appears to be coordinated to both oxygens of the 
carboxylate. The zinc atom is penta-coordinated (T 5, trigonal bipyramidal 
configuration) to the catalytic triad and the two phosphinyl oxygens (Fig. 3-
12). The two phosphinyl oxygen-zinc bonds are distinctly different in length, 
at 2.56 A (Zn-OAT) and 1.84 A (Zn-OBl), as is the case with other 
phosphinate-metalloprotease complexes. In the bidentate coordination one of 
the bonds is usually longer than the other, on average 2.54 A and 2.14 A in 
the case of carboxypeptidase A- and leucine aminopeptidase-phosphonate 
complexes (Kim & lipscomb, 1990; Strater & lipscomb, 1995; Alberts et aI., 
1998). Stromelysin-3, or matrix metalloprotease 11, also has unequal 
bidentate coordination phosphinate bonds in its complex with a phosphinic 
inhibitor (means of 2.89 A and 2.33 A for the two P-O bonds in the six 
molecules of the asymmetric unit) (Gall et al., 2001). A general feature of the 
binding site of RXPA380 to tACE-g13 is the considerable space between sub-
site residues and the inhibitor. Only 12 atoms (from 8 amino acid residues, 











Th!s !S comparable with 10 atoms (of 6 amino aCids, plus three waters and 
zinc) within 3 A of lisinopril in 1086. despite the fact that RXPA380 (44 non-H 
atoms) is a considerably larger molecule than lisinopril (29 non-H atoms) 
~,.~ '('\ 
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Figure 3-12. Stereo view of catalytic zinc ~nta-coordination in the active site of tACE-
g1J comp lexvd with RXPAJ80. Di~taflC<>S bvtwvv n zinc ~nd coordin ating atom~ ~how" 
in A"g&trOm~. 
3.6.3.2. 52 sub-site 
Positioning of an inhibitDf sub-group at the S2 position has not been 
pre .. iously observed in lACE-inhibitor complexes, as the inhib;tors were all 
Type II or Type III inhibitors (Fig, 1-4) The benzene ring has hydrophobic 
,',n 30, interactions with H - am F - , the only side chains that are within 4 A of It 
(Fig 3-13) A hydrogen bond between the amine n;trogen of AJOO and the 
carbony l oxygert of the Cbz group (2,46 A) iikely prevents any fiexlb!e motion 
of the Cbz moiety, keeping it fixed in the side pocket (Fig 3-13) 
3.S.3.3. 81 sub-site 
The hydrophobic phenyl ring irt the PI position interacts with the Cr, of 8 '" 
proximally, and with FS12 and V" < distal to the P2 and zinc-binding groups 
Nothing else in the 81 jXJcket is close enough to make significant interactions 
with the ring All of the previously determined ACE-inhibitor CQmplexes (With 











as a phenylpropyl group, and it occurs ill essentially the same orientatiOIl in all 
a/them (Fig 1_7 , 3_14) , 
H4I~ _ 
F1I..ure 3-13. S2 and S1 residues of tACE -gl3-RXPA380, Residue side Ch3ills (except 
A . S'" om\ A'''') hava baan am;lt"~ for clarity_ 
51' sub-site 
This sub-site is occupied by a pseudo-proline moiety. i.e, a proline with the 
amine nitrogen substituted by a carbon. described as the C, carbon. This 
carbon is in the R stereo-connguralion. in contrast with the adjacent C" 
carbon. which is S, as would be expected in proline. All alignment of active 
site residues from 1086 and the tACE-g13 - RXPA380 complex confirms the 
prediction that the R-collfiguralioll of the C, carbon. together with the esselltial 
S-configuratioll at the PI' C" (Cushmall et ai , 1977) a!laws the prolyl ring to 
adopt the same directional conformation as the Iysyl chain ill lACE lis inopril 
(Georg;adis et aI., 2004) (Fig 3-14) Notably, the carbonyl oxygell of A""A is 
marginally displaced away from the Inhibitor (relative to the correspollding C-
O bOlld III tACE-l lsmopnl) , probably due to the presence of a carbon atom 
(C, ) ill place of the H-bond donor. In tACE- tisinopril this cart:x:my! oxygcll 










Figure 3-14. Stereo view of Cn alignment of tACElI.36NJ-li~inop,il (y .. Uowl and tACE_ 
1113-RXPA380 (purple. r.m.s.d. = 0.24 AI produces subSlanti~1 correspondence 
twtw .... n inhibitor .... sidu g~ , En~lapfil and c~pto".-il are essen~ally fully superimposab~ 
OVQr li~ inopril. Thg ov" rlapping z;"c c~tions are shown in mauve Ithat of tACE-gI3-
RXPA380 i~ light .. , in shadeL 
3.6.3.5. 52' sub-site 
The 52' pocket of tACE·gl3-RXPA380 complex is a large binding pocket 
(Fig 3-i5) There are 10 residues with in 5 A of the tryptophan side chain 
(Table 6) in addilioo. there are Iwo waler molecules, wat l1 that is 
coordinated to the C-tenninal carboxylate, ar.j wat13, which mediates the 
interaction between the tryptophan N , and the E370 side chain 
figure 3-tS. SteM" vi<>w of ,tACE-.g13 S2' pocket containing RXPA380 tryptophan 
resKlue, The 10 amino aC Kl res,dues within 5 A 01 th .. P2' tryptoph an a s well as E" and 
0 '" ~ ... ~hown in hall-and-stick nOlaUon, Water molecules arc shown oS maroon 











0 453, whose side chain is further than 6 A from RXPA380, forms a hydrogen 
bond with a water molecule in the upper recesses of the 52' pocket; this 
interaction is likely to keep the side chain in an angled conformation, away 
from the P2' tryptophan. 
3.6.4. tACE-g13-RXPA380 vs ACE N-domain sub-sites 
A Cu alignment (544 atoms, r.m.s.d. :::: 0.77 A) of tACEg-13-RXPA380 and the 
ACE N-domain complexed with lisinopril (pdb code 2c6n, A chain) ailows a 
comparison of the sub-sites of the two domains (Fig. 3-16). 
The major difference in the 52 pocket is the presence of tyrosine in place of 
F391 of tACE. This may provide opportunity for a weak (due to length: 3.57 A) 
hydrogen bond between the tyrosine hydroxyl and carboxy group of Cbz. At 
Pi the slight shift of the phenylpropyl ring is consistent with the presence of a 
polar threonine residue in place of V518 (Fig. 3-16). Both these substitutions 
are consistent with the selectivity of the N-domain for RXP407, which has a N-
terminal aspartate residue. 
The differences between N- and C-domain 5 l' pockets have been described 
previously (Natesh et aI., 2003; Corradi et aI., 2006). One noteworthy pOint is 
that the alignment of the A chain of N-domain-lisinopril reveals particularly 
close contact between the carbonyl oxygen of A 332 (equivalent to A 354 in 
tACE) and the CII of the pseudo-proline (2.0 A; cf. 2.9 A in tACE-g13-
RXPA380). In the lisinopril complexes this oxygen forms a hydrogen bond 
contact with the Iysyl amine nitrogen. The variance in length of this H-bond 
between the domains (2.6 A N-domain-lisinopril vs 2.9 A tACE-lisinopril), 
together with the clash already mentioned, suggest that there may be 
conformational restraints on the N-domain that prevent it from easily 











The 52' pocket comparisons reveal several differences. The replacement of 
V379 and V3SO with 5357 and T35s in the N-domain increases the polar nature of 
the pocket, and reduces the possibility of stabilising van der Waals' 
interactions with the indole ring. 0 453 in the C-domain is replaced by a 
ol.ut.am§te. whose side chain faces away from the P2' residue, precluding any 
reorientation occurs at the site of another conservative substitution. In tACE 
wat13 is H-bonded to both E376 and the indole nitrogen. This connectivity is 
not possible in N-domain due to replacement of the E by 0 354• Not only is this 
side chain shorter than that of glutamate, but it also faces into the protein, well 
away from the inhibitor. (It must be noted, however, that both chains of the N-
domain structure contained no modelled water residues in the region of the 
P2' pocket, most likely due to lower resolution of 3.0 A) Taken together, these 
changes allow the 52' pocket to be considered as the major determinant sub-
site in the difference in binding affinity of RXPA380 to the C- and N-domains. 
Analysis of the internal pockets in tACE-g13-RXPA380 and the N-domain-
lisinopril structure (pdb code 2c6n, A chain) uncovers substantial differences 
in the overall conformation of the 51' and 52' pockets. CA5Tp analysis 
(Binkowski et aI., 2003) revealed that the N-domain 51' and 52' pockets are 
effectively contiguous when probed with a 2.5 A-radius probe, forming a large 
cavity of volume 1152 A 3. By contrast, although the pocket comprising the 
tACE-g13 52' residues also incorporates a number of the 51' residues, at 857 
A3 this pocket is much smaller than that found in the N-domain. This 
difference in volumes and the substitution of 52' C-domain residues by 
smaller residues in the N-domain (T2825, V3795 , v3SD-r, E3760), together point 
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Figure 3-16, Stereo vi~w comparison of tACE_g13 (_Codomain) (purple) and ACE N· 
domain (gold) s ub~ite r<ls idues, with particular gmphasis on 52' pockgt, and with 
RXP,I,380 in th g activo site. lACE numbenng is used, sites where N·domain residu 9s 
differ ore indicated with gold letters. Selected distanc~ (in II) indicateo with y ellow 
dotted lin gs. All waler mol 9cul9s (rgd sphgres) aro from tACE_gI3_RXPA3aO s tructu,o_ 
The overa!l stabilisat:on of the RXPA380 molecule by means of Interactions at 
the 32' pocket and Ihe rigid conformalion maintained due to the R-S 
configuration of the pseudo-proline together seem to make the differellce With 
respect to selectivity. Compound 9. an RXPA380 analogue in which pseudo-
proline and tryptop!lan are replaced by pseudo-alanine and alanine, has 
identical K; values for the N- and C-domains, Indeed, Ihe measLlred K; values 
(0_8 nM in each case) were lower than that of RXPA380 with C-dOOlain 
(Georgiadis lOt ai, 2004) , suggesting thai the sLib-Slte interactions do not 
necessa ri ly enhance binding, but merely provide a means for discrimination 
between the two domains, It may be speculated that the S2' pocket is 
sufficlentty large to allow blnd!ng of vaflous sizable P2' constituents. For 
example, compound 11 is another RXPA3BO analogue , which has pseudo-
arginine in P2' and is othelWise identical to RXPA380. It binds C-domain with 
K; '" 9 nM which IS quite similar to that of RXPA380 (Georgiadis et at , 2004) 
But the interactions of this group With the S2" pocket of N-domain appear not 
to be as non-complementary as those of the indole ring , since K, '" 200 nM for 
the N-domain_ Therefore differences in the S2' pocket distinguish the two 











3.6.5. Comparison of experimentally determined fACE· 
RXPA380 and modelling predictions 
In light of the difficulties faced in terms of obtaining co-crystals of tACE-g13 
and RXPA380, the in silico docking and modelling of tACE and RXPA380 was 
undertaken concurrently. In the event of the successful co-crystallisation of 
the complex and subsequent structure solution and refinement, it is 
worthwhile to compare the experimental structure with the structure predicted 
from in silico modelling. 
The energy-minimised tACE-RXPA380 molecular model (RXPA380MM) was 
found to have more residues found in the generously allowed/outlier regions 
of the Ramachandran plot. This was not considered to be a serious mark 
against drawing conclusions about the possible binding of inhibitors at the 
active site of the models. The minimisation algorithm allows the free 
movement of atoms to attain the most overall energetically stable state, and 
no constraint was imposed on phi and psi angles during the iterative 
minimisations. Nevertheless, the Ramachandran plot of the residues of the 
active site (residues wholly or partially within 5 A of the inhibitor) was 
preferentially examined carefully in order to ensure that no gross distortions of 
the active site region were overlooked. 
The Co alignment of tACE-g13-RXPA380 and RXPA380MM revealed an 
r.m.s.d. of 1.55 A. Alignment of residues within 5 A of the tACE-g13-
RXPA380 gave an r.m.s.d. of 1.15 A. Immediately evident in this alignment 
was the general correspondence of all atoms with the clear exception of the 
inhibitor's P2 Cbz group. The pseudo-proline rings were also not so well 
aligned, especially at the C[ carbon. The P2' tryptophan side chain and the P1 
phenylpropyl group aligned particularly well. The all-inhibitor alignment 
(r.m.s.d. ::: 1.07 A) and the same alignment excluding the Cbz group beyond 
the amine nitrogen (r.m.s.d. ::: 0.61 A) indicate the level of similarity between 











Table 6. Predictions of tACE-RXPA380 conformation at S2' pocket compared with 
experimentally determined structure. Distances of 12 residues (in bold) predicted to be 
within 5 A of RXPA380 (Georgiadis et at, 2004). Tryptophan - S2' side chain distances 
are measured in current modelled structure (RXPA380MM) and experimental structure 
(tACE..g13-RXPA380). Additional residues within 5 A are included. Shortest inte,· 
atomic distance between residue and tryptophan side chain is given in Angstr6ms. 
Residues IS RXPA380MM prediction tACE-g13-RXPA380 
QD1 3.5 NEZ - C61 3.1 NEZ - C61 
T282 3.5 Cy2 - NE1 4.3 Cy2 - NE1 
eaTS 6.5 Oe2 - M:1 6.1 OE2- NE1 
V379 4.3 Cy1 - C{2 4.8 Cy1 - CIl2 
V380 4.1 Cy2 - C42 4.8 Cy2 - C<2 
0 415 4. 7062-C~3 3.7 061- C~3 
lY'" 5.3001 - C(2 6.2002 - NE1 
F457 3.1 C4 - Cj3 3.5 C~ - Cj3 
p460 6.5 Ce2 - C01 6.5 Ce2- C{3 
y520 3.8011 - Cj3 3.30rJ-CI3 
y523 3.8 CI52-CI3 3.7 CI.\2-CI3 
F627 3.9 Cc:-CI12 4.5 CE1 - CE3 
H383 3.8 Cy -CC:3 3.7 Cy - C<3 
Wat11 4.50-CI.\1 
Wat13 3.40- Nf:1 
a residues in bold are 52' residues from Georgiadis at al. (2004). In each column the first-
named atom is from the residue side chain, and the second atom is of the RXPA380 
tryptophan residue. The italicised residues are those more than 5 A from the RXPA380 
tryptophan. 
Equally significant are the discrepancies between the positions of important 
residues in the P2' pocket. The prediction underestimates the distances 
between valines 379 and 380 and the tryptophan residue by 0.5 and 0.7 A 
respectively (Table 6). The predicted positions of T282, F457, and F527 also 
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Figure 3-17. Stereoscopic view of ali901"'elll of Insight lI.gctlvral~d tACE_RXPA3S0 
model (orange) and experimentally deiermiooed tACE-g13-RXPA380 (purple). 32 
inhibitor atoms (the Cbz group w~s excluded) were aligned with r.m.s.d." 0.61 A. All 
wale, mo!ecul"s (red spheres) a .... from the lACE-g13-RXPA380 structure, 
The corlsistent valence forCe f!eld (C-VFF) has Its iimitatlons with regard to its 
applicability to systems with oonded metals. It is a classical force field, and 
has been parameterised for amino acids, proteins and small molecules, As 
described in Materials and Methods, this force field 'IS not parameten&ed to 
recognise LinC and therefore the solution around thiS was to llse magnesium 
Instead . Howe\ler. the parameters assigrled to the metal as a result are 
automatically generated, and thus not fully appropriate. The extenSible 
systematic force field (ESFF) is a more appropriate force field to use, as it 
both recogn'ses zinc expliCitly and relies Orl atomiC parameters that are 
combined with empirically derived rules , WhiCh are used to generate force 
field parameters. 
Another cntic;sm of the RXPA380MM lies in the method of gerleratlon of an 
average structure The use of an average conformation may result In a highly 
distorted starting model for minimisation, and <Jltlmately a distorted final 
model, particularly if the minimisaliorl is not allowed to go on to convergence 











These criticisms aside, the model-generated structure bore substantial 
similarity to the experimentally determined structure. The previously unseen 
P2 group is the notable exception, as it was not in the correct position. It 
appears that the orientation of this group may have been much closer to that 
of the tACE-g13-RXPA3BO complex if the methyl phenyl group had been 
attached to the other oxygen of the carboxy group during the building of the 
inhibitor. (But there was no obvious reason to choose one oxygen over the 
other.) Put another way, it may be that the modelling allows too much 
flexibility in this region where it appears that the spatial constraints imposed 
by the protein are reduced. The crystal structure 8-factors of the inhibitor 
atoms (all below 30 A2) give no evidence of such a reduction, and therefore 
do not support much flexibility for the P2 group. 
In any case, optimisation of the protocol, particularly in terms of the use of the 
best force field, ESFF, may allow for the confident generation of more putative 
ACE-inhibitor complexes that give insight to domain-selective binding without 






















4.1. Protein expression, purification and 
crystallisation 
The expression and purification of the glycosylation mutant tACE-g13 has 
proved to be a solid foundation upon which to extend structural investigations 
of angiotensin-converting enzyme in our laboratory. Completed and ongoing 
work has seen the stable expression of tACE-g13 in Chinese hamster ovary 
ceils, the crystallisation and structure determination of native tACE-g13 
(Gordon et aI., 2003; Watermeyer et aI., 2006), and now the co-crystallisation 
of tACE-g13 with the potent C-domain-selective inhibitor RXPA380. The co-
crystallisation conditions were essentially identical to those for native enzyme 
crystallisation, with the addition of a 4-fold molar excess of inhibitor yielding 
co-crystalS. 
4.2. Data collection, structure solution, refinement 
and analysis 
The successful use of the protein crystallography beamline BM14-UK at the 
ESRF in Grenoble, France, is a milestone for South African structural biology. 
The structure of tACE-g13-RXPA380 has been solved to 2.7 A resolution by 
molecular replacement, and refined in CNS. 
The structure of tACE-g13-RXPA380 represents the structure determination 
of an ACE-type I inhibitor complex; that is, of an inhibitor with a P2 
constituent group. All published structure complexes are of ACE with type II or 
type III inhibitors. This P2 group occupies a large pocket and interacts 
hydrophobically with nearby residues. 
The P1 phenyl propyl group and P1' pseudoproline groups are in close 












The P2' group has been considered the determinant of C-domain selectivity. 
The interactions revealed by the three-dimensional structure firmly support 
this hypothesis. particularly in view of the interactions of hydrophobic V379 and 
V3SO with the tryptophan indole ring. and of the water molecule that is H-
bonded to both the indole nitrogen and E37s. The shorter aspartate residue in 
the N-domain replaces this glutamate. and so the interaction is in all likelihood 
lost. 
4.3. Comparison of modelled tACE-g13-RXPA380 
predictions with experimental structure 
The modelling of the interaction between tACE and RXPA380 provided an 
opportunity to assess the quality of the predicted model with respect to the 
experimentally determined structure. The INSIGHT II-generated model agreed 
well with the experimental structure, with the explainable exception of the P2 
group. It appears that the inversion of the carboxyl moiety of the P2 group 
could not be corrected during the INSIGHT II dynamics run. 
Thus the structure has revealed a binding mode very similar to predictions 
made by the synthetic chemists responsible for RXPA380 (Georgiadis et aI., 
2004), and in modelling experiments carried out locally. These results suggest 
that one can look with confidence upon modelling predictions, although there 
were a number of methodological issues to consider. The appropriate choice 
of force field was the most important of these. 
4.4. Directions for future work 
Now that the hypothesis that the 52' pocket interactions are the major driver 
of selectivity has been confirmed, it remains to be seen just how the 
RXPA380 molecule interacts with the N-domain. In conjunction with such 
putative crystallographic work, it would also be useful to attempt co-











synthesised by Dive and colleagues (Dive et aI., 1999; Dive et aI., 2004; 
Georgiadis et al .. 2004). The data they have already collected on inhibition. 
I 
together with the current study, point to th~ likelihood that although C-domain 
selectivity can be gained or lost by a P2' 9hange alone, the selective binding 
of an inhibitor is due to subtler cumulath(e effects at the binding site and 
possibly beyond that. The dynamic as~ects of enzyme catalysis have 
historically proven difficult to elucidate. I For example, nuclear magnetic 
resonance spectroscopy studies (Galanis etl
l 
ai., 2003) have not yet provided a 
view of the entire enzyme in solution (the progress is reviewed by 5pyroulias 
et a!. (2004)). In addition, although normal-~ode analysis work has suggested 
a mechanism by which the enzyme may op~n to allow in substrate or inhibitor 
(Watermeyer et aI., 2006), the accessibm~ of the active site has not been 




Another useful direction to explore i$ the kinetic and structural 
characterisation of tACE-g13 active site mu~ants, particularly at the 51' and 
I 
52' sub-sites. This work is ongoing in our I~boratory, and may bring some 
insight into the individual contributions of residues to the selectivity. 
\ 
The modelling protocol has proved to be useful, although it is not yet optimal. 
I 
After optimisation of the protocol the modell;ng and analysis of binding for 
other phosphinate inhibitors is also likely to su~gest ways in which to enhance 
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